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I. INTRODUCTION 
The Human Genome Project resulted in the publication of the human genome 
sequence (covering ~99% of the euchromatic genome) in 2004 
(INTERNATIONAL HUMAN GENOME SEQUENCING, 2004). As of today, 
however, the exact function of many genes is still unknown. If more information 
could be gained on the functionality of our genes under all kinds of physiological 
and pathological conditions, a much better concerted effort could be made for the 
development of new therapies, the detection of predispositions to certain diseases, 
or novel approaches to medicine in fields like personalized medicine or gene 
therapy.  
Since there are considerable homologies between the genes of humans and other 
mammals, it is possible to transfer large parts of the functional data gained about 
the genome of the latter to our effort to understand the human genome more 
profoundly (and vice versa). 
The genomic sequence of several domesticated animals has already been 
published in its entirety, amongst those the genome of the house mouse (Mus 
musculus). Mice have been used for medical experiments for many decades or 
even centuries (MORSE et al., 1978). Due to their many advantageous traits as a 
mammalian model organisms (a large litter size; a fast generation cycle; a small 
body size and correspondingly small keeping costs; a large number of inbreed 
strains; an already existing very large pool of information on mouse physiology 
and on the general traits of mice as experimental subjects (SCHOFIELD et al., 
2012); the hardiness and docility of domesticated mice) it seems much more 
feasible to gain insightful data on the mode of operation of the entirety of the 
mouse genome, transcriptome and proteome in the near future than it would be 
with any other mammal, including humans. 
Of course, to understand such complex systems, research on them has to be 
distributed amongst a large number of smaller projects. Each project then deals 
with a single gene or a group of interacting genes under specific physiological or 
pathological conditions.  
The present project evaluated the relevance of the adhesion molecule E-Cadherin 
(alternatively: “cadherin-1”, “epithelial cadherin”) and its respective gene CDH1 
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for the homeostasis of the liver in general, as well as its impact on tumors of the 
liver like hepatocellular carcinoma (HCC). 
This specific outlining of the project was chosen with a reason: HCC is one of the 
leading causes of cancer-related deaths worldwide (JEMAL et al., 2011), and also 
quite difficult to treat curatively in humans. Any information gained on CDH1 
interaction with HCC could possibly lead to an improvement of treatment options 
or even better, prevention of the disease in the future.  
This project was a collaboration between the “Lehrstuhl für Molekulare Tierzucht 
und Biotechnologie” (Veterinärwissenschaftliches Department, Tierärztliche 
Fakultät, LMU München) and the “Molekulare Gastroenterologie” (Medizinische 
Klinik und Poliklinik II, Campus Großhadern, Klinikum der Universität München, 
LMU München). 
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II. REVIEW OF THE LITERATURE 
1. Genetically modified mice 
1.1. Functional analysis of the genome (in any organism) 
 
Fig. 1: “Bully whippet”, adapted figure from: (MOSHER et al., 2007). 
To analyze the function(s) of a certain gene in an organism, it is quite useful to 
compare a population in which the gene is missing (or otherwise altered: 
overexpressed, for example) to another population in which the gene is not 
altered. The differences between the populations are likely to be caused by the 
lack or alteration of the gene in question and give good hints to the functions of 
the gene. A good example for this would be cattle of the double-muscled Belgian 
Blue breed (KAMBADUR et al., 1997) or the “bully whippet” (MOSHER et al., 
2007), in which the mutation of the myostatin gene causes a very muscular 
phenotype if the mutation is homozygous (Fig.1). 
While it sometimes is possible to find and isolate subpopulations displaying a 
(preferably single locus) genetic alteration by sheer chance, for systematic 
research it is considerably more efficient to create such populations artificially (in 
microorganisms, plants, experimental animals, cell cultures, etc.). There are two 
major options: forward genetics or reverse genetics. 
Forward genetics (phenotype-driven): Use of naturally occurring or artificially 
induced random mutations in a population. If individuals displaying an alteration 
of phenotype are detected, they are separated (possibly breed into a new line), the 
phenotype is characterized thoroughly and their genome is checked for alterations. 
The techniques used today for this purpose include, but are not limited to: 
localization of the mutation site using classical animal husbandry in combination 
with markers like Simple Sequence Repeats (SSRs), genome sequencing (many 
modern methods being derivatives of the Sanger sequencing method), quantitative 
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mRNA expression analysis, and many more (SIMON et al., 2012). A nowadays 
often heard catchphrase and state-of-the-art technique is ‘‘third-generation 
sequencing’’ i.e. single-molecule sequencing, which helps to decreases errors 
which might be present in methods (like Sanger sequencing) that rely on 
amplification of DNA (GUPTA, 2008). 
Reverse genetics (genotype-driven): A specific gene is deleted, overexpressed or 
otherwise altered by gene manipulation techniques. The resulting population is 
then checked for any changes of phenotype that might have appeared. First 
established in yeast (STRUHL, 1983), it can also be used in mammals 
(CAPECCHI, 1989). 
Induction of random mutations can be attained by dosing model organisms with 
chemical substances like the mutagen N-ethyl-N-nitrosourea (ENU), for example 
(BROWN, 1998). While intrinsically a tool for forward genetics, the large 
collections of generated mouse strains with identified mutations frequently serve 
as a tool for reverse genetics studies.  
Specific genes can be targeted, for example, by making use of homologous 
recombination (CAPECCHI, 1989), or additional copies of a specific gene can be 
brought into the genome at a random location (COSTANTINI & LACY, 1981; 
GORDON & RUDDLE, 1981). 
1.2. Why mice? 
The biological properties of mice make them a favorable mammalian model 
organisms: they are easy to handle, replicate fast and generate relatively low 
initial and maintenance cost even when generating large cohorts to analyze 
(SCHNEIDER, 2012). Laboratory mice also normally do not endanger research 
personnel with either severe physical attacks or dangerous zoonoses, since mice in 
well managed research facilities are kept strictly separated from direct or indirect 
contact with wild mice and are preferably specific pathogen free (SPF). In 
contrast, working hazards might be considerable if farm animals or even wild 
animals are handled for experiments (LANGLEY, 1999). 
The nucleic acid sequence of the genome of the house mouse (Mus musculus) has 
been published in its entirety almost simultaneously with the human genome 
(MOUSE GENOME SEQUENCING et al., 2002; AUSTIN et al., 2004), and the 
sequence of 17 strains of mice (encompassing most of the mice strains commonly 
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used in research) had already been reported by 2011 (SCHOFIELD et al., 2012). 
It is generally accepted that there is a high degree of homology between the 
genomes of mice and humans (WINTER, 1988; DELEZOIDE & VEKEMANS, 
1994; VENTER et al., 2001) and that the mouse is thus a good model organism to 
help understand the human genome (ARBOLEDA & VILAIN, 2011).The huge 
array of technologies available to alter the genotype of mice and to analyze their 
phenotype additionally contributes to establish mice as one of the best suited 
experimental models for modern biomedical research (GLASER et al., 2005; 
CHEON & ORSULIC, 2011).  
For example, some of the tools for the genetic manipulation of mammals work 
best in mice or are even exclusive to mice. Gene targeting by homologous 
recombination in stem cells and subsequent blastocyst injection  has been well 
established and continually improved in mice (LONGENECKER & KULKARNI, 
2009) but is far from being a feasible technology even in other popular lab 
animals like rats (BRADLEY et al., 1984; LONGENECKER & KULKARNI, 
2009; DECHIARA et al., 2010; MEEK et al., 2010). Technologies commonly 
used to create genetically modified mice are discussed in the next chapter. 
The availability of biotechnological tools like embryo transfer and superovulation 
greatly help not only in the creation but also in the rapid distribution of novel 
genetically manipulated mouse strains. In mice, embryo transfer is well-
established today and enables to bring animals safely into specific pathogen free 
facilities or to purge a mouse strain of a pathogen (SUZUKI et al., 1996). The fact 
that many very efficient cryopreservation protocols exist for mouse embryos 
today (TSANG & CHOW, 2010) does not only aid in transport but also makes 
inexpensive long-term storage possible. Mouse sperm can also be preserved in 
liquid nitrogen (MARSCHALL & HRABE DE ANGELIS, 1999; MAZUR et al., 
2008), and recently methods have been developed to store mouse sperm for a few 
months in non frozen media or even at room temperature for short periods (LI et 
al., 2011). All of this greatly reduces the cost of keeping genetically modified 
animal model strains for later use and also helps to reestablish mouse facilities, if 
they become contaminated or after unforeseen disasters like fire or flood.   
1.3. Creation of genetically modified mice 
The report of the first gene-manipulated animal was published in 1974 
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(JAENISCH & MINTZ, 1974). Mice which passed those alterations to their 
offspring were first reported in the early eighties (COSTANTINI & LACY, 1981; 
GORDON & RUDDLE, 1981). Since then it has become possible to insert almost 
any desired DNA sequences into the genome of laboratory mice, which for 
example could lead to overexpression of proteins coded by the inserted artificial 
sequence. It is also possible to target specific, already known genes through the 
use of homologous recombination (GLASER et al., 2005). 
There are many different technologies to create genetically manipulated mice. 
Two of those technologies are used very commonly today and can be considered 
crucial for modern biotechnological research with transgenic mice: DNA 
microinjection in pronuclei and homologous recombination in embryonic stem 
cells with subsequent blastocyst injection. Both techniques have different 
advantages and disadvantages. DNA microinjection in pronuclei of fertilized 
oocytes has been developed in the early 1980s. Compared to other techniques 
(like transduction, where a virus-vector is used on multicell embryos) it has the 
advantage that the resulting animals are not chimeras and only very seldom 
mosaics (HARBERS et al., 1981).  
The DNA to be inserted must be designed carefully, and often it is not predictable 
how efficient the design will be. For example, it often is not known how many 
regulatory elements of the gene are needed and where they are located. Therefore 
it is sometimes better to include as much of the gene as possible, including introns 
and upstream sequences. Sometimes regulatory sequences are contained in 
adjacent genes and in this case it may be difficult to include all regulatory 
elements. 
Together with the gene of interest, additional DNA can or must be inserted. For 
example, promoter sequences (this could be an organ-specific or an ubiquitously 
expressed promoter) and elements that act as reporters (easy to detect sequences 
or sequences coding a detectable transcript that does not affect the physiology of 
the test organism) can be included.  
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Fig. 2: Injection of fertilized one-cell eggs. Based on: (SI-HOE et al., 2001) 
After the DNA has been designed, amplified and purified, it can be microinjected 
into fertilized one-cell mouse eggs (Fig 2). This requires precise equipment 
(holding pipettes, injection pipettes, microinjection chamber, etc.) and skilled 
personnel, as well as enough mouse eggs in exactly the right stadium (this can be 
achieved by checking donor mice for the time of “plugging”, which marks the 
time of insemination by the male mouse). 
After injection, the eggs are transferred to the oviduct of pseudopregnant females 
(females inseminated by non-fertile male mice). 
The DNA is normally integrated during the one-cell stage, only in rare cases it is 
integrated in later stages (which would result in mosaic offspring). How the 
inserted DNA is expressed depends heavily on the integration site. The integration 
site as well as the number of copies inserted at that site is random and cannot be 
dictated by the researcher. It is possible that the integration interrupts the function 
of another gene, and the resulting offspring has to be carefully checked for this 
unwanted effect (SI-HOE et al., 2001). 
Homologous recombination in embryonic stem cells with subsequent blastocyst 
injection works only in mice, and has only been established for certain strains of 
mice. It was first established for the “129” strain. Because the 129 strain genetic 
background is not desirable for many experimental setups, gene-manipulated 129 
mice are generated and then backcrossing is used to give them another strains 
background while keeping the gene-manipulated site. This is time-consuming, and 
adequate backcrossing becomes increasingly more difficult the closer the gene-
manipulated sequence is linked with (undesirable) 129 traits (SEONG et al., 
2004). Strains nowadays deemed suitable as alternatives to 129/SvJ mice include 
C57BL/6N, C57BL/6JOla, DBA/2N, DBA/1Ola, BALB/c and FVB/N 
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(CARSTEA et al., 2009). Nonetheless, many popular gene-manipulated mice 
today are of 129 origin because they were either developed before the existence of 
alternatives or because 129 ES cells are still considered to be easier to work with. 
The ES cells of mice seem to have higher frequencies of homologous 
recombination than do other cultured mammalian cells. Still, for a successful 
experiment, the DNA that is used for homologous recombination has to be 
designed carefully. Most notably, the DNA has to be isogenic, and the homology 
arms (e.g. the parts that are similar in the artificial DNA and the native DNA of 
the stem cells) have to be long enough (GLASER et al., 2005). 
After stem cells positive for the homologous recombination have been obtained, 
they can be injected into a blastocyst. This blastocyst preferably hails from a 
mouse strain with a coat color that is different from the ES cell donor. After the 
blastocyst has been successfully implanted in a surrogate mother mouse, an 
embryo derived from cell lines of four different parent mice develops. The tissues 
of different genetic makeup are not rejected because the embryos immune system 
is non-existent at first, and later is tolerant to the already-present and “known” 
proteins of the other genetic strain. The embryo is chimeric in nature (this can be 
easily detected if the fur is spotted, e.g. made up of different cell lines), but its 
offspring is not chimeric (and hopefully some of the offspring is derived from the 
desired cell line, which is the case if the ES cells 
formed at least some parts of the germline of the 
chimera) (SEONG et al., 2004). 
Fig. 3: A chimeric mouse with typically variegated coat 
color. Taken from: the public domain. 
1.4. Conditional knockout (Cre/loxP) 
Limiting the genetic alteration to a single organ is favorable because it prevents 
the problem of a multitude of effects in multiple organs. If a gene is deleted from 
all cells of an experimental animal, interesting (but only faint) effects might be 
missed in one specific tissue because they are obscured by massive effects in 
another organ. Conditional knockout makes focusing on analyzing the phenotype 
in the specific tissue easier. Also, the gene to be analyzed, or rather the lack of it, 
could have a lethal impact on early embryonic stages (LARUE et al., 1994). 
Conditional knockout can sometimes be a necessity to circumvent this problem. 
II. Review of the literature     9 
One common approach to conditional knockout is the Cre-loxP system. This 
system has been developed in the nineteen eighties (SAUER, 1987) and has been, 
in parallel with similar systems or even combined with them, in ample use for 
targeted gene-manipulations since then (ROSSANT & MCMAHON, 1999).  
Cre/loxP and analogous systems can be used to delete a sequence from the 
genome of a cell, even if the cell is part of an already fully developed multi-cell-
organism (like a mouse). The deletion happens under defined conditions and can 
be designed to affect all cells or only a certain type of cells in that organism.  
The sequence could be, for example, a complete gene, part of a gene or a 
sequence regulating a gene. The defined condition can be topical/spatial (e.g. a 
single organ only) or temporal (e.g. only after timed, extrinsic or intrinsic triggers 
are present), a combination of both or even more complex conditions (METZGER 
& CHAMBON, 2001; KOS, 2004).  
To create a conditional knockout mouse using cre-loxP, typically (at least) two 
genetically modified mice strains are used (NAGY, 2000). In the first mouse 
strain the sequence in question is flanked by two loxP-sequences. The flanked 
sequence is also often called a “floxed sequence”. The loxP-sequence is not native 
to eukaryotes, instead originating from the bacteriophage P1 (STERNBERG & 
HAMILTON, 1981). The sequence is short (ATAACTTCGTATA-GCATACAT-
TATACGAAGTTAT) and can be inserted exactly at the desired sites by gene 
manipulation techniques using homologous recombination. If the sequence is 
inserted at a site where it does not obstruct the normal reading of the DNA (e.g. in 
non-functional parts of the noncoding DNA), it alone has no effect. The sequence 
does not code protein, and it does not cause recombination events by itself. It does 
enable an enzyme called “Cre” to delete the area between two loxP sites, though. 
In this process, one loxP site is removed together with the flanked sequence and 
formed into a cyclic structure, while the other loxP site remains at the point where 
the DNA has been reconnected. Depending on the orientation of the loxP sites, 
alternatively, the sequence could be inverted instead, but this variant is normally 
not used for the purpose of generating knockout mice (KOS, 2004). 
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Fig. 4: In this example of conditional tissue specific knockout, the creatine kinase 
promoter directs Cre expression only in muscle, or the albumin promoter directs 
Cre expression only in liver. Accordingly, the gene PPARG (PPAR-γ) is deleted 
tissue-specific only. Based on: (KOS, 2004) 
In the second mouse strain, the enzyme Cre is expressed. The word “Cre” can be 
understood as a contraction of the words “creates recombination” or alternatively 
“cyclization recombination". Like the loxP-sequence, the sequence for Cre is not 
native to the mammalian genome. If the Cre sequence is inserted at a location 
where it is under the control of the same promoter as a protein native to the 
organism (or is inserted together with a specific promoter), Cre can be expressed 
in a tissue- or cell type-specific manner. A Cre under the same promoter as an 
organ-specific protein would be only present in this organ (for example: under the 
same promoter as albumin, which is produced in the liver only). A Cre under a 
time-specific promoter would be active at certain times (for example: the albumin 
promoter is only active after the mouse actually begins production of albumin, but 
not in the early embryonic stages). If the promoter is only active in the organism 
under certain living conditions, the expression can be triggered intentionally (for 
example: after feeding the organism a diet containing heavy metals). 
Alternatively, the Cre sequence could be fused with the sequence coding for a 
ligand-binding-domain (LBD) of a hormone receptor. Cre fused to a ligand-
binding-domain can only enter the nucleus (and elicit its effect there) if it has been 
activated by its ligand (a hormone). If the LBD is mutated and only reacts to 
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artificial hormone-like substances (and not the native hormone), the effect of Cre 
can be controlled by application of a substance (e.g. injection of tamoxifen, for 
example, activates an artificial Cre-ER
T
) (METZGER et al., 1995). 
Once those two mouse strains exist, they can be intercrossed. If the offspring 
carry both the flanking loxP sequences as well as the ability to produce Cre, the 
flanked area of their genome is deleted after the aforementioned conditions have 
been fulfilled (Fig. 4). Since there are a multitude of related systems that can 
delete genes or trigger them in addition to Cre/loxP, it is possible to create model 
organisms containing an array of different conditions for the knock-in and/or 
knockout of multiple DNA sequences (ANASTASSIADIS et al., 2009).  
1.5. Analyzing the phenotype of genetically manipulated animals 
With the creation of mouse mutants, the genotype has been altered. The next 
question is how this affects the phenotype. In the case of genes that only influence 
a single locus trait this questions can be answered easily, at least if the trait can be 
detected with the bare eye or with the technology available to the researcher. 
But some traits are influenced by several genes, and sometimes there are 
redundant genes that take over if the gene of interest is mutated (ZHANG, 2012). 
In addition, some genes are pleiotropic (influencing two or more distinct 
phenotypic traits) and this further complicates understanding the relationship 
between the gene of interest and the phenotype (BECKERS et al., 2009; 
STEARNS, 2010). Some genes have varying importance during different stages 
of life. Consequently, analyzing a phenotype can be challenging and time 
consuming. 
Even if genotype and phenotype are thoroughly analyzed, this is often not the 
whole information needed to transfer the research results to real-life questions of, 
say, human medicine. This is because the phenotype under challenging conditions 
(a disease, for example) is still not taken into account. Mice are normally housed 
under standard conditions and are not at all challenged with the same factors that 
contribute to human disease. Those conditions have thus to be created artificially. 
This could, for example, involve confronting mutant mice with pathogens 
(LECUIT, 2005), narcotics (HALL et al., 2012), lifestyle specific diet (part of the 
“envirotype”) (BECKERS et al., 2009) or carcinogens (FRESE & TUVESON, 
2007; CHEON & ORSULIC, 2011). In addition to giving better insight into the 
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gene or protein of interest´s function, this approach can possibly also contribute to 
the establishment of relevant animal models of human diseases. 
2. E-Cadherin 
E-cadherin is a protein that is important for cell-cell adhesion. In humans, it is 
coded by the gene CDH1 (obsolete gene symbols are UVO; CDHE; ECAD; 
LCAM; Arc-1 or CD324). In mice, the equivalent gene is called Cdh1 (Source: 
NCBI recources Website 2012). 
The word itself can be understood as a contraction of some of the traits of the 
protein: “e-“ stands for “epithelial”, while “cadherin” can be understood as 
“calcium-dependent adherin” (YOSHIDA-NORO et al., 1984). Although the 
official (mouse) protein name according to the NCBI homepage (as of 2012) is 
cadherin-1, we have chosen the E-cadherin designation because it is more 
commonly employed in peer-reviewed publications. 
2.1. Cadherins in general 
The cadherin superfamily is huge, comprising of at least 350 members, and 
cadherins can be found in an amazingly wide range of organisms (HULPIAU & 
VAN ROY, 2009). Classical cadherins are typically named according to the organ 
or tissue in which they are most prominent and/or have been found first (e.g. 
N-cadherin = “neural cadherin”, etc.). 
Structurally, all cadherins have the EC domain (extracellular cadherin) containing 
repeating amino acid sequences of about 110 residues (ß-folded). This definition 
of the cadherin superfamily includes many proteins whose function has not yet 
been characterized well. The number and arrangement of the EC domains varies 
between different cadherins and linkers between successive EC domains are 
stabilized by Ca
2+
 (some exceptions to this rule exist). Adhesion, even between 
classical cadherins, can be due to a great variety of different cadherin-cadherin 
interfaces and many of the mechanisms are still not well understood. The 
structural basis of cadherin binding to other proteins is often unclear (BRASCH et 
al., 2012), although some have already been described, like E-cadherin binding to 
NKLRG1 and to internalin. The natural killer cell receptor KLRG1 binds to a 
highly conserved site on classical cadherins (LI et al., 2009). Internalin, on the 
other hand, is a major invasion protein of Listeria monocytogenes. It can form a 
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complex with its human receptor E-cadherin (SCHUBERT et al., 2002). 
Cadherins (E-, N-, P-cadherin, etc.) preferentially interact with cadherins of the 
same type in a homophilic manner when connecting cells and may thus help 
sorting heterogeneous cell types (TAKEICHI, 1990). 
For cell adhesion, cadherins are dependent on Ca
2+
 (VAN ROY & BERX, 2008). 
A weak form of cell adhesion is achieved by trans-interaction between cadherins 
on opposing cells surfaces. For stronger cell-cell-adhesion, cadherins can be 
clustered (NELSON, 2008).  
Another way to achieve strong cell adhesion is through changes in the actin 
skeleton. Cadherins can exert a strong influence on actin and vice versa by 
interacting with it in sophisticated ways (Fig 5). Previously it was assumed that 
cadherin binds to actin directly 
(through the cytoplasmic proteins α- 
and β-catenin). Recently it has been 
indicated that their influence might be 
mediated indirectly, using an allosteric 
switch in α-catenin (NELSON, 2008).  
 
Fig. 5 Cadherins, catenins and the actin cytoskeleton influence each other, often 
reciprocally. Based on: (NELSON, 2008).  
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The so-called “cadherin-catenin-complex” (and its mode of operation in the cell 
adhesion and migration) is not understood completely, but models exist that can 
explain some of its effects (Fig. 6). 
Fig. 6: This model can explain the regulation of cytoskeleton and membrane 
dynamics by the cadherin–catenin complex. Cell-cell adhesion is characterized by 
reduced membrane dynamics. E-cadherin presence can be controlled via catenin, 
and absence of E-cadherin leads to increased membrane dynamics, which enables 
cell migration. Based on: (NELSON, 2008). 
2.2. E-Cadherin structure, expression and relevance 
E-cadherin is considered a “classical cadherin” and a “type I cadherin”. Being the 
founder member of the cadherin family, E-cadherin is often seen as the 
prototypical cadherin. Its importance for adhesion has been under investigations 
by scientists since about 1977 (VAN ROY & BERX, 2008; HULPIAU & VAN 
ROY, 2009). 
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E-cadherin is a 120 kDa protein in its mature form (OZAWA & KEMLER, 1990). 
It has five extracellular, immunoglobulin-like domains (EC1 to EC5). It also has a 
transmembrane α-helix and an extended intracellular domain that binds β-catenin 
(SCHUBERT et al., 2002). EC5 differs from the other domains (EC1 to 4) and an 
alternative naming has been proposed (VAN ROY & BERX, 2008). 
E-cadherin has a remarkable gene structure because each of the EC domains is 
coded by two to three exons, with different exons coding for different 
EC domains, despite the repeating nature of the domains. Also, the boundaries of 
the exons do not correlate with the EC boundaries in the mature protein (Fig. 7). 
All of this markedly differs from coding sequences of some other cadherins. The 
gene CDH1 contains 16 exons and intron #2 is of special note because it is very 
probable that it contains regulatory sequences (BERX et al., 1995; VAN ROY & 
BERX, 2008). 
 
Fig. 7: The human CDH1 gene structure. Posttranslational modification of the 
protein yields a mature protein with a sequence markedly different from what 
could be expected on the basis of the gene sequence. Based on: (VAN ROY & 
BERX, 2008) 
It is clear that presence of (E-)cadherin is needed for normal cell-cell-contact and 
cell-sorting, but also down-regulation of E-cadherin is often important if tissues 
need to be reorganized or are formed de novo, such as during embryogenesis. The 
modulation of E-cadherin is part of a process whereby formerly epithelial tissue 
temporarily gains mesenchymal qualities (epithelial-mesenchymal-transition = 
EMT) (KOKKINOS et al., 2010). 
Soluble E-cadherin fragments are sometimes increased in serum from patients 
with skin diseases (FURUKAWA et al., 1994) and loss of E-cadherin expression 
has been found to correlate with certain skin diseases (FURUKAWA et al., 1997). 
As the name “epithelial cadherin” already implies, E-cadherin is especially 
important and pronounced in epithelial tissues and conditional knockout of Cdh1 
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in epithelial tissue often has severe consequences for experimental animal health 
(SCHNEIDER et al., 2010). 
E-cadherin plays a role in the defense against pathogens and its loss or mutation 
has been associated with decreased barrier function against germs (SCHNEIDER 
et al., 2010). Interestingly, it can also serve as a receptor for pathogens such as L. 
monocytogenes (VAN ROY & BERX, 2008). 
Cadherins are important in the assembly of tight junctions, adherens junctions and 
desmosomes (LEWIS et al., 1997b; TUNGGAL et al., 2005). Recently it has been 
hinted that many cell junctions not only are major players in cell-cell adhesion, 
but also are more important acceptors of cell signaling pathways than it was 
assumed previously (GREEN & JONES, 1996; MCCREA et al., 2009). Through 
its importance for cell junctions, E-cadherin (or lack of it) could possibly have 
impact on the most diverse functions of cells (pathways, regulation of passage of 
needed or harmful molecules, osmotic balance, etc.). 
For experimental set-up of mouse models, it is important to note that E-cadherin 
has crucial functions during embryogenesis (GUMBINER, 2005). Essentially, 
using constitutive Cdh1 knockout models to study the function of E-cadherin in 
adult mice is pointless because the embryos die around implantation (LARUE et 
al., 1994). 
2.3. Connection of E-cadherin with tumors 
E-cadherin is the major cell-cell adhesion molecule in epithelial cells, and 80% of 
human cancers derive from epithelial cells (SEMB & CHRISTOFORI, 1998). 
E-cadherin interacts with several proteins important to structure and restructuring 
processes (ß-catenin, actin) (BEAVON, 2000; GUMBINER, 2005) and thus it is 
an important player in EMT, which in turn plays an important part in 
tumorigenesis (TIAN et al., 2011; TIWARI et al., 2012). While EMT normally is 
a physiological function important to embryogenesis (KOKKINOS et al., 2010), 
tumor cells can also be more “successful” by using EMT mechanisms. 
Analysis of cells from tumors of different origins taken from patients often 
showed a decrease of E-cadherin expression and/or mutations in the coding 
sequence. This also proved to be the case for some hepatocellular carcinoma 
(HCC) samples (MATSUMURA et al., 2001; CHIEN et al., 2011). Also, soluble 
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E-cadherin fragments are often increased in serum from cancer patients 
(FURUKAWA et al., 1997). 
While a connection between E-cadherin loss and the development or growth of 
tumors is widely accepted, the relationship could be of quite diverse nature. Is the 
loss of E-cadherin a consequence of tumors being active (and using mechanisms 
akin to EMT)? Or is it just a co-causality, where some common mechanism in 
tumors reduces E-cadherin, but E-cadherin loss does not really contribute to the 
aggressiveness of the tumor? Or does loss of E-cadherin make the transition of 
normal cells to “successful” tumor cells easier? 
Support for the latter hypothesis comes from both animal models and certain 
studies from human medicine. Animal models of conditional loss of E-cadherin 
have shown susceptibility to tumorigenesis in organs like the mammary gland 
(DERKSEN et al., 2006) and humans carrying a mutation in the CDH1 gene have 
a strong predisposition for certain types of cancer, namely Hereditary Diffuse 
Gastric Cancer and lobular breast cancer (KAURAH & HUNTSMAN, 1993). 
Decreased E-cadherin does often increase invasiveness of tumor cells, but by no 
means is this correlation between E-cadherin level and tumor aggressiveness 
always the case. Tumor cells with normal E-cadherin levels can be very 
aggressive (NIEMAN et al., 1999; CHRISTIANSEN & RAJASEKARAN, 2006) 
and in certain tumors (such as inflammatory breast cancer) E-cadherin is 
consistently upregulated regardless of histologic type or molecular profile 
(KLEER et al., 2001; BERX & VAN ROY, 2009). 
Upregulation of cadherins other than E-cadherin (N-cadherin) can add to tumor 
invasiveness and metastasis, even if E-cadherin is not reduced. This leads to the 
speculation that cadherins act as “homing devices” that can help tumor cells enter 
into parenchyma if they manage to express enough of the “correct” cadherin for 
the tissue (e.g. N-cadherin for mesenchymal tissue) (HAZAN et al., 2004).  
E-cadherin is generally regarded as a tumor suppressor and loss of the protein 
seems to be a crucial step for many tumors to be “successful”. Despite this, 
E-cadherin upregulation might even promote aggressiveness in certain cases. 
Examples for this have been shown in high-grade gliomas (E-cadherin expression 
is supposed to be rare in normal adult human nervous system tissue) (LEWIS-
TUFFIN et al., 2010) or ovarian carcinoma (ovarian surface epithelium is 
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normally free of E-cadherin, expressing N-cadherin instead) (SUNDFELDT, 
2003).  
Metastases from prostate cancer also seem to be more aggressive in certain tissues 
(like bone) if they express E-cadherin. It has been hypothesized that tumor cells 
can enter organs far away from the original tumor site if they have low E-cadherin 
expression, but that they need to “exit EMT” and might upregulate E-cadherin so 
that they can actually grow at sites of metastasis (PUTZKE et al., 2011). 
The cleaved fragments of E-cadherin have been linked with a possible oncogenic 
potential. Mature E-cadherin has a molecular weight of 120 kDa, but can be 
cleaved into an extracellular N-terminal 80 kDa fragment (this soluble fragment 
can enter intracellular space and the bloodstream) and an intracellular C-terminal 
38 kDa fragment. Several mechanisms have been proposed to explain how 
cleavage or the resulting fragments could increase tumor aggressiveness (DAVID 
& RAJASEKARAN, 2012). Cleavage of E-cadherin could also be an explanation 
why sometimes tumors with high E-cadherin are equally or even more aggressive 
than tumors with low expression. 
Similar to human medicine, in practical veterinary medicine loss of E-cadherin is 
often associated with increased aggressiveness of tumors in patients (pets) 
(SARLI et al., 2004; GAMA & SCHMITT, 2012). 
3. Hepatocellular carcinoma (HCC) 
HCC can develop in humans and many other mammals. Since the main focus of 
the project underlying this thesis was to gain information relevant to human HCC 
by using a mouse model, the details of HCC in domesticated animals other than 
the mouse will not be discussed extensively. It is sufficient to say that HCC  is 
rather uncommon but has been reported in several domesticated animals 
(GHOLAMI et al., 2006), that it has some qualities similar and some qualities 
different compared to human HCC (LIPTAK et al., 2004) and that treatment 
options are available (SEKI et al., 2011). In humans, HCC is one of the most 
important cancers worldwide (Fig. 8), being diagnosed in more than half a million 
patients per year worldwide. Of the primary liver cancers, HCC is encountered 
much more often than other primary liver cancers like cholangiocellular 
carcinoma (SHIMODA & KUBOTA, 2007). Liver cancer is the fifth most 
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common cancer in men and the seventh in women (EL-SERAG, 2011) and a 
leading cause for cancer-related death (JEMAL et al., 2011), ranked amongst the 
top three in males. 
 
Fig. 8: World map showing regional variation in the estimated age-standardized 
incidence rates of liver cancer, based on data from the World Health 
Organisation. The incidence rates (number of cases per 100,000 persons) pertain 
to both sexes and all ages. Based on: (EL-SERAG, 2011) 
3.1. HCC in humans 
The factors causing HCC in humans are diverse, including aflatoxins 
(GROOPMAN et al., 2008; LIU & WU, 2010), nitrosamines (MITACEK et al., 
1999) and other contaminants of food (ADAMSON, 1989), alcohol abuse, genetic 
predispositions and many more. But possibly the most important factor is hepatitis 
caused by viral infection (GOMAA et al., 2008). Several different, not closely 
related viruses causing hepatitis are known today: A, B, C, D and E. Some 
typically are blood-borne diseases (C, for example) while others typically are 
smear infections (A, for example). Of the viruses, only B and C are decidedly 
relevant for HCC (MICHIELSEN et al., 2005). Worldwide 78% of HCC is 
estimated to be attributable to HBV (53%) or HCV (25%) (PERZ et al., 2006). 
Prevalence of hepatitis is quite different from region to region and also dependent 
on the social group. The poor hygienic conditions under which people are forced 
to live in some areas contribute to this as well as a personal high-risk lifestyle. 
Thus hepatitis, and consequently HCC, typically is a disease more prevalent in 
people who live (or have previously lived) in developing countries. Due to the 
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close correlation of HCC to virus-induced hepatitis in a distant past, the tumor 
also seems to afflict predominantly middle-aged to old people rather than young 
individuals. This reasoning, of course, cannot be applied unrestricted to regions 
where hepatitis is so prevalent and/or medical standards are so low that infants 
regularly already get infected perinatally (MICHIELSEN et al., 2005). 
Since hepatitis B and C are blood-borne infectious agents (in addition, B is often 
transmitted sexually), certain sub-groups of the population are much more at risk. 
Intravenous users of drugs are especially vulnerable to infection. As an interesting 
remark, this is quite possibly a reason for the very high rate of HCC amongst 
Japanese that would not be expected for a medically well-covered country like 
Japan. It is speculated that Japan had a very high rate of intravenous 
amphetamine-abusers in the turmoil period after the Second World War. 
Consequently, HCC in Japan mostly afflicts the very old and is predicted to 
decrease substantially once this generation ceases to exist (MORIYA et al., 1999). 
Before the advent of general alertness to the threat of AIDS and other blood-borne 
diseases, infection with hepatitis did occur easily even without a personal high-
risk lifestyle in people of all walks of life (CHIARAMONTE et al., 1996) through 
poorly sterilized medical equipment or treatments involving serum preparations 
(SCHREIER & HÖHNE, 2001). The problem persists, since occasionally hygiene 
in medical facilities in some regions is still far below the necessary level (YERLY 
et al., 2001). All in all, since neither hepatitis nor alcohol abuse, nor the dangers 
of food contaminants can be expected to be eradicated in the near future, HCC 
will continue to be an important disease worldwide. 
3.2. HCC in mice (induced by diethylnitrosamine) 
Fig 9: Diethylnitrosamine structure. 
Mice are a popular model organism for studying different 
cancer types (FRESE & TUVESON, 2007). While different 
protocols for the induction of HCC in mice exist, the most common involves the 
intraperitoneal application of diethylnitrosamine (Fig. 9) (abbreviation DEN; 
synonym: DANA; DENA; NDEA; N,N-diethylnitrosamine; N,N-diethylnitrous 
amide). The cancer potential of nitrosamines in general is well known and has 
been a subject of interest since humans often get exposed to nitrosamines with 
certain food (JAKSZYN & GONZALEZ, 2006) or if they work in certain 
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industries (rubber factories, for example) (SPIEGELHALDER & 
PREUSSMANN, 1983). It should be noted that the cancerogenity of nitrosamines 
in humans is very strongly suspected but, unlike in rodents, not proven definitely 
(ABNET, 2007). 
DEN is a nitrosamine which has a relatively low toxicity compared to its 
cancerogenity (DRUCKEY et al., 1967; CHRISTENSEN et al.) and as such it is 
well suited for the induction of tumors without causing early dropouts in the 
experimental group. Several variations exist concerning the amount of carcinogen 
given, the age at which it is given, and possibly which substances (barbiturates for 
example) are applied in addition to DEN for further promoting tumor 
development (LEENDERS et al., 2008). 
DEN itself is not necessarily the primary tumor causing agent by direct 
interaction, but it becomes a powerful carcinogen through biotransformation (with 
a resulting carbonium ion, which can act as an alkylating agent), for example by 
cytochrome P450 oxigenation (LEWIS et al., 1997a). Since the liver has a very 
high concentration of cytochrome P450, a lot of the biotransformation of DEN 
will happen there (RAJEWSKY et al., 1966). In addition, the venous blood from 
almost all unpaired abdominal organs is directly passed to the liver and a large 
amount of the DEN injected will reach the liver parenchyma very fast. Due to all 
these factors, after i.p. injection, DEN causes tumors mostly in the liver and in all 
other organs the effect will be much smaller.  
Like in humans (JEMAL et al., 2011), mouse males are far more often affected by 
HCC than females and it is suspected that estrogen has a protective effect 
(NAUGLER et al., 2007). 
It should be noted that there has been some research on the exposure of personnel 
to nitrosamines in animal facilities doing tumor research (ISSENBERG & 
SORNSON, 1976) and a number of safety measures should be taken when 
working with such substances (fume hood, gloves, safety goggles, safe disposal of 
feces of the animals, good ventilation, etc.). 
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III. ANIMALS, MATERIALS AND METHODS 
1. Animals 
Since the original creation of the employed mouse lines (POSTIC et al., 1999; 
BOUSSADIA et al., 2002) was not part of this thesis and only crossing of already 
genetically manipulated mice strains was done, the gene manipulation procedure 
will not be described in detail.  
1.1. Cdh1 conditional knockout mice 
Mice were obtained from The Jackson Laboratory via Charles River. The mouse 
was originally created by Rolf K Kemler (BOUSSADIA et al., 2002). The mouse 
has floxed and has the strain name “B6.129-Cdh1tm2Kem/J”. The mouse has 
floxed Cdh1 (or rather: important exons of Cdh1 are floxed) and if crossbred with 
a mouse expressing the enzyme Cre, the floxed exons become lost (Fig. 10). A 
description of the genotype, phenotype and background of this line can be found 
(as of February 2013) under the following link:  
http://jaxmice.jax.org/strain/005319.html 
1.2. Alb-Cre transgenic mice 
Mice were obtained from The Jackson Laboratory via Charles River. The 
transgenic mouse was originally created by Mark Magnuson (POSTIC et al., 
1999) and has the strain name “B6.Cg-Tg(Alb-cre)21Mgn/J”. The mouse 
expresses Cre in the liver, and can be used to delete floxed sequences specifically 
in this tissue. A description of the genotype, phenotype and background of this 
line can (as of February 2013) be found under the following link:  
http://jaxmice.jax.org/strain/003574.html 
1.3. Mouse breeding procedure 
To ablate E-cadherin specifically in the liver, mice expressing Cre in the liver 
only (Alb-Cre) were mated with mice carrying a floxed Cdh1 allele. Mice were 
maintained in the C57BL/6 background. Offspring was genotyped and through 
planned mating, mice homozygous for the floxed allele (Cdh1
fl/fl
) were generated 
to be used as controls (L-Control) while mice carrying, in addition, the Alb-Cre 
transgene, formed the experimental group (L-Cdh1
del/del
), which underwent liver-
III. Animals, Materials and Methods     23 
specific Cdh1 deletion (Fig. 10). It was taken care that L-Cdh1
del/del
 mice were 
only hemizygous for the Alb-cre transgene. 
 
Fig. 10. Schematic representation of the floxed (Flox) Cdh1 allele and the deleted 
(Del) allele after Cre-induced recombination. Exon 6 to 10 are lost in the process. 
1.4. Animal maintenance 
Animals were kept under SPF conditions in macrolon cages type II (type III if 
group housing was possible). The light cycle was set to 12 hours light and 
12 hours darkness. Mice were provided with wood chip bedding, a wooden or 
plastic shelter, enrichment in the form of paper towels to shred and a spinning 
wheel, ad libitum access to water and standardized rodent chow (standard rodent 
diet (V1536, Ssniff, Soest, DE). Care was taken that enrichment was standardized 
and identical for L-Cdh1
del/del
 and L-Control group. 
1.5. Approval of animal testing and ethical guidelines 
The guidelines and laws regarding experiments involving animals in Germany 
were observed (TierSchG, related laws and regulations; as well as guidelines by 
the GV-SOLAS, FELASA, responsible veterinary authorities, etc.).  
A permit for experimentation on animals was obtained for this thesis project. The 
respective file numbers at the responsible veterinary authority (Regierung von 
Oberbayern) are: Az. 55.2-1-45-2531.3-21-09 (training & education purposes) 
and Az. 55.2-1-54-2532-125-09 (Injection of a cancerogenic substance). 
2. Mouse genotyping 
The designation given to the mice used for internal use in the animal facility and 
the lab was “fl/fl | +/wt” for knockout and “fl/fl | wt/wt” for animals without 
knockout, whereas “fl/fl” described the floxed status of the Cdh1 sequence (in 
both alleles: homozygote) and “+/wt” or “wt/wt” described the presence or 
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absence of Cre, respectively.  
For generating the mice to be entered into the experiments, “fl/fl | +/wt” mice 
were crossed with “fl/fl | wt/wt” mice, which resulted in litters in which the 
genotype of the parents was present again. (Fig. 11).  
 
Fig. 11 Breeding protocol. If random distribution of chromosomes (represented 
by bluish or rose bars) is assumed, 50% off the offspring are knockout mice.  
Polymerase chain reaction (PCR) was employed to confirm the presence of two 
floxed Cdh1 alleles and to determine the presence or absence of Cre. 
To improve comprehensibility, the above-mentioned designations will generally 
not be used in this thesis. Instead, in all graphs and in the text, mice will be 
referred to as “L-Cdh1
del/del
” (= liver-specific Cdh1-recombination/deletion) and 
“L-Control” (= littermates with floxed, but not deleted Cdh1). 
2.1. Tissue collection 
Two variations of sample collection were used. Mice aged 5 to 6 weeks were 
marked by the use of ear holes and/or notches using an ear punch device. Then a 
small part of the end of the tail (ca. 2 to 4 mm) not containing vertebrae was 
clipped using scissors. The tail wound was sealed by the use of Histoacryl
® 
liquid 
skin glue (B.Braun, Melsungen, DE). For the mice that were scheduled for tumor-
induction at an age of two weeks, it was essential to know the genotype before the 
induction. Thus, the samples had to be collected earlier (at the age of 3 to 6 days), 
and tattooing of the pads was used for marking. The ink (Pelikan, Hannover, DE) 
was injected using a fine (30G) syringe. After collection, the tail clippings were 
stored at -20° C. 
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2.2. Extraction of DNA from mouse tail tips 
For DNA preparation, a modified version of the Promega Corporation protocol 
(Wizard® Genomic DNA Purification System) was used. 
A mixture containing 120 µl EDTA (0.5 M, pH 8.0), 500 µl Nuclei Lysis Solution 
(Promega, Mannheim, DE) and 17.5 µl proteinase K (concentration, Roche, 
Mannheim, DE) was added to a  1.5 ml microcentrifuge tube containing a fresh or 
frozen mouse tail tip and was incubated overnight at 56°C with gentle shaking. On 
the next day, RNA was eliminated with RNase Solution (Roche, Mannheim, DE). 
Protein Precipitation Solution (Promega, Mannheim, DE), in combination with 
centrifugation, removed protein. DNA was precipitated with isopropanol (Merck, 
Darmstadt, DE). Using centrifugation and 70% ethanol, the DNA was washed and 
subsequently suspended in 50 µl Rehydration Solution (Promega, Mannheim, 
DE). If PCR failed due to an overabundance of DNA, further dilution was done 
with bidistilled water. 
2.3. Principle of the polymerase chain reaction (PCR) 
Polymerase chain reaction is a well-known technique in almost all labs working in 
the field of life sciences. Thus, only a short overview will be presented here. 
The double strand of DNA can be replicated into two double strands of DNA 
using the enzyme polymerase. A number of steps are required for that: 
1) Separation of the double strand through heat  
2) Annealing of forward + reverse primers at a lower temperature 
3) Activity of the polymerase enzyme 
Only the sequence between the primers is amplified (including the binding site). 
The cycle can be repeated multiple times, producing a very large number of DNA 
sequence copies. Unless a real-time PCR system is used, the usual method of 
detection and evaluation of the PCR product is electrophoresis in an agarose gel. 
DNA copies with the same length will form a “band”, visible after the gel is 
stained (typically with ethidium bromide). 
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2.4. Assay procedure and PCR protocols 
PCR was done in 8-tube-strips (G. Kisker GbR, Steinfurt, DE), using 1 µl of 
sample at a DNA concentration of about 50 ng/µl. For every sample, 19 µl master 
mix was added.  
Mastermix preparation (per sample): 
 PCR buffer, 10x (Qiagen, Hilden, DE)    2.00 μl 
 dNTPs, 1 mM (MBI Fermentas, St. Leon-Rot, DE)  2.00 μl 
 Q-Solution (Qiagen, Hilden, DE)    4.00 μl 
 MgCl2, 25 mM (Qiagen, Hilden, DE)    1.25 μl 
 Sense primer, 2 µM       1.00 μl 
 Antisense primer, 2 µM       1.00 μl 
 Bidistilled H2O       7.65 μl 
 Taq Polymerase, 5 U/µl (Qiagen, Hilden, DE)   0.10 μl 
 
The PCR-machine/thermal cycler (Biometra, Göttingen, DE) was programmed for 
the following temperature cycle: 
5 min 94°C (DNA denaturation) 
[begin repeatable cycle, x35] 
1 min 94°C (DNA denaturation) 
1 min annealing temperature (55°C or 58°C) 
2 min 72°C (elongation) 
[end repeatable cycle] 
10 min 72°C (elongation) 
Infinite time at 4°C (cooling/storage) 
 
The forward/reverse primers used for genotyping were specific for the Cre 
sequence (58°C annealing temperature) for sites framing a flox sequence of Cdh1 
(55°C annealing temperature). The number of cycles was 35 (occasionally 
increased to 37). The primer sequences are listed in the “Materials” section on 
page 45. 
Electrophoresis was done in a 1.5% agarose gel (containing ethidium bromide) in 
TAE buffer at 120 V of concurrent flow and detection was done under ultraviolet 
light. 
50x TAE buffer: 
 TRIS       242 g 
 Glacial acetic acid     57.1 ml 
 EDTA ph8.0, 0.5 M     100 ml 
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3. Basic overview of mouse sections 
Before section, mice body weight was documented. In case of drawing blood, 
mice were anesthetized. Mice were killed by cervical dislocation using the blunt 
side of a knife blade. Mice younger than 1 or 2 weeks (depending on the pubs 
size), were killed by cutting the spine close to the head using scissors. 
After killing the mice, the body was put belly-up on a tissue-covered polystyrene 
plate and the paws were affixed using pins. The fur was dampened with isopropyl 
alcohol or disinfectant to prevent hairs from contaminating samples and the furry 
outer skin was cut open (one cut along the linea alba and one cut orthogonal to it, 
roughly 1 to 2 cm cranial of the pelvis) and partly removed from the belly (and, if  
required, also from the thorax). Then the abdomen was cut open in a similar 
manner and the flaps of tissue were pinned down on the right and left side to give 
easy access to the innards of the animal. After inspection and sometimes 
photography of the opened mouse, the organs of interest were removed and 
samples gained and/or organ weights and sizes were documented.  
Organ samples were either frozen on dry ice, stored in formaldehyde, or kept in 
RNAlater® (Ambion [part of Invitrogen], Darmstadt, DE). The remaining body 
was either kept in 4% formaldehyde in PBS for the eventuality of further analysis 
or was disposed as appropriate (Category 1 material, Regulation (EC) No 
1774/2002). 
10x PBS pH 7.4: 
 NaCl       80 g 
 KCl       2 g 
 KH2PO4      2.4 g 
 Na2HPO4      14.4 g 
 Bidistilled water up to     1 l 
 Adjusted to pH 7.4 with HCl 
 
4% buffered formaldehyde solution: 
 Paraformaldehyde     40 g 
 10x PBS pH 7.4     100 ml 
 NaOH, 5 M       250 µl 
 Bidistilled water up to     1 l 
 Dissolve under heat before correcting pH 
 Adjusted to pH 7.4 with HCl 
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4. Assessment of E-cadherin loss on protein-level  
4.1. Collection of liver samples 
Immediately after killing the animal and opening of the abdomen, the gut was 
pulled away from the liver, thus making the liver`s stem accessible for fixation 
with pincers. By carefully applied pulling force (and cutting with scissors where 
necessary), the liver was removed. On a flat surface the livers lobes were spread 
out and, using the gall bladder and the outlines of the lobes as orientation, the 
lobes were identified. The lobes were separated from each other and, using 
scissors, the lobe chosen for protein analysis was cut into small pieces 
(ca. 2 x 4 mm). The pieces were immediately placed on dry ice, and after being 
frozen through they were collected in pre-cooled 1.5 ml plastic microcentrifuge 
tubes or cell culture plates and stored in a -80°C freezer. 
4.2. Preparation of liver samples 
During the procedure, all samples that were not currently manipulated were stored 
on ice-cold water. 5 ml round-bottom tubes (Falcon/BD, Heidelberg, DE) were 
filled with 400 µl to 600 µl Laemmli buffer (1x concentration) and tissue samples 
(ca. 3 mm diameter). 
Laemmli buffer stock (5x concentration): 
 1M TRIS pH 6.8   65.5 ml  
 Glycerol    100 ml  
 0.5 M EDTA pH 8.0   2.0 ml  
 SDS     20 g  
 Bromophenol blue   a tiny amount (ca. 0.2 g or less)  
 Ad 200 ml bidistilled H2O  
 
A homogenizer (Homogenizer Miccra, ART Labortechnik, Müllheim) was 
applied at 23,500 rpm for 30 seconds. After transfer to an eppendorf 1.5 ml cup, 
the sample was heated to 95°C in a thermomixer (Eppendorf, Hamburg). If 
required, reducing conditions (cleavage of disulfide bonds) were created by 
adding 1 µl of 2-Mercaptoethanol per 20 µl of Laemmli buffer before heating to 
95°C. After cooling down with ice for 5 min and subsequent centrifugation at 4°C 
at 13,000 rpm (Table centrifuge 5417R, Eppendorf, Hamburg, DE), the 
supernatant sample was either used immediately or stored short-term at -20°C. 
For measuring protein concentration (“Bicinchoninic acid assay” = “Smith 
assay”) (SMITH et al., 1985), a standard curve ranging from 0 to 8 mg protein/ml 
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was produced, using bovine serum albumin (= BSA; Roth, Karlsruhe). Measuring 
of standard and samples was done in 96-well cell culture plates with flat-based 
wells (Becton Dickinson, Heidelberg).  
10 µl sample (or 10 µl standard) was mixed with 40 µl PBS pH 7.4 as well as 4 µl 
4% CuSO4 solution (Sigma-Aldrich, Deisenhofen,DE) and 196 µl bicinchoninic 
acid (Sigma-Aldrich, Deisenhofen,DE). Duplicates were pipetted (e.g. 2 wells 
with 110 µl each) before incubation at 37°C for 30 min. Absorption at a 
wavelength of 560 nm was measured using a Microplate Reader (Tecan, 
Männedorf, CH). 
4.3. Electrophoresis and blotting 
The Mini Protean® 3 cell system (Bio-Rad, Munich, DE) was used to separate 
proteins. Acrylamide gel was prepared in a glass container under continuous 
motion (by a magnetic stirrer). Separating gel (5 ml) was poured between the 
glass plates of the rack and covered with 1 ml bidistilled water. After 
polymerization for 45 min, the water was removed. Stacking gel (about 1 ml) was 
poured on top of the separating gel, and the system was fitted with a comb (10 or 
15 teeth) to create pouches. After 30 min of polymerization, the gel was ready for 
use. 
Gel acrylamide concentration: depending on the protein molecular weight, either 
10% or 12% separating gels were used. 
Separating gel (10%): bidistilled water   4.0 ml 
1.5 M Tris (pH 8.8)    2.5 ml 
30% acrylamide    3.33 ml 
10% SDS     100 μl 
10% ammonium persulfate   50 μl 
Temed     5 μl 
Separating gel (12%): bidistilled water   3.35 ml 
1.5 M Tris (pH 8.8)    2.5 ml 
30% acrylamide    4.0 ml 
10% SDS     100 μl 
10% ammonium persulfate   50 μl 
Temed     5 μl 
Stacking gel (5%):  bidistilled water   7.0 ml 
1.5 M Tris (pH 8.8)    1.25 ml 
30% acrylamide    1.5 ml 
10% SDS     100 μl 
10% ammonium persulfate   125 μl 
Temed     5.5 μl 
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The gel was placed into the electrophoresis apparatus and the chambers were 
filled with electrophoresis buffer. The comb was removed and one sample (diluted 
to contain 40 µg protein) was pipetted per pouch. 
Molecular weight standard: PageRuler
TM
 prestained protein ladder (#26616 
[former Fermentas # SM0671], Thermo Scientific, St. Leon-Rot, DE). 
SDS-PAGE electrophoresis buffer: 
 Tris      30.3 g 
 Glycine     144 g 
 SDS      10 g 
 bidistilled water up to   1 l 
Protein was drawn into the stacking gel at 100 V for 15 min. Separation of protein 
was done at 140 V for about 90 min (depending on estimated protein molecular 
weight). 
For semi-dry blotting, a ball-pen labeled PVDF membrane (Millipore, Billerica, 
MA, US) was activated with methanol (p.a.) for 15 min on a seesaw. On the 
blotting apparatus (Bio-Rad, Munich, DE) a stack of different layers was arranged 
(from bottom to top): extra-thick blotting paper (Bio-Rad, Munich, DE), 
membrane, gel, extra-thick blotting paper. The stack was covered with transfer 
buffer (20 ml 10x transfer buffer + 40 ml methanol + 140 ml bidistilled water) and 
fixated with the electrode lid. 
10x transfer buffer:  
 Tris      58.2 g 
 Glycine     29.2 g 
 SDS      3.7 g 
 bidistilled water up to   1 l 
The blotter was set to 15 V for 1 hour. Afterwards, the membrane was flushed 
with TBS-T. For blocking, 5% instant skimmed milk powder (Roth, Karlsruhe, 
DE) in TBS-T was applied for 1 hour at room temperature or overnight at 10°C on 
a seesaw. 
10x TBS buffer:   
 Tris      30 g 
 NaCl      80 g 
 bidistilled water up to   1 l 
 pH corrected to 7.4 with HCl 
 
TBS-T buffer: 
 1x TBS with 0.1 % Tween
®
20 (Sigma-Aldrich, Deisenhofen, DE)  
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4.4. Detection of protein 
Antibodies were diluted (see below) in 1% instant skimmed milk powder in 
TBS-T. Incubation of antibodies was done in 50 ml falcon tubes in an unheated 
rotating hybridization oven (H.Saur, Reutlingen, DE). 
The membrane was flushed with TBS-T and then incubated with the primary 
antibody for 1 hour at room temperature or overnight at 10°C. After washing with 
TBS-T, the secondary antibody was applied for 1 hour at room temperature or 
overnight at 10°C. Following washing with TBS-T, an ECL solution (#34076; 
#34077, Thermo Scientific, Rockford, IL, US) was applied and incubated for 
1 min on a seesaw. CL-XPosure Film (Thermo Scientific, Bonn, DE) was exposed 
to the membrane (depending on intensity of the fluorescence between 3 seconds 
and several hours) and developed (Curix60 Tabletop processor, Agfa HealthCare 
Corporation, Greenville, SC, US). 
Primary antibodies diluted: 
 goat vs. E-cadherin (#AF748, R&D Systems, Wiesbaden-Nordenstadt, 
DE) at 1:1000 
 mouse vs. actin (#691001, MP Biomedicals, Eschwege, DE) at 1:5000 
 rabbit vs. GAPDH (#14C10, Cell Signaling, Frankfurt-Main, DE) at 
1:5000 
Secondary antibodies (HRP conjugated) diluted: 
 donkey vs. rabbit (#NA934V, GE Healthcare, Munich, DE) at 1: 10.000 
 sheep vs. mouse (#NA931V, GE Healthcare, Munich, DE) at 1: 10.000 
 donkey vs. goat (#sc-2033, Santa Cruz, Dallas, TX, US) at 1: 10.000 
5. Evaluation of gene expression at the RNA level  
5.1. Collection of liver samples for RNA analysis 
Since we assumed liver RNA expression to be heavily influenced by the circadian 
rhythm as well as by food intake, care was taken to standardize this influences as 
good as possible. Mice of all groups scheduled for RNA analysis were put on a 
grid at 9 o’clock a.m. with no access to chow, where they could not reach other 
organic material (bedding, feces). Water was given ad libitum. Sections were 
32                                                                                              III. Animals, Materials and Methods 
started exactly 6 hours later and performed as fast as possible. Preparation of liver 
for RNA analysis was done by extracting a central piece of the left liver lobe, ca. 
4x4x8mm. This work was done on an ice-cooled glass plate (ca. 4°C). The piece 
was stored in RNAlater® (Ambion [part of Invitrogen], Darmstadt, DE) at 4°C 
overnight and was transferred to a -20 or -80°C freezer on the next day. 
5.2. RNA expression analysis using Agilent Microarray 
Extraction of RNA from tissue, cDNA synthesis for microarrays and 
measurement using Agilent Microarray technology (Agilent Technologies, Inc., 
Santa Clara, CA, US) was kindly done by members of the group of Dr. Helmut 
Blum (LAFUGA, Gene Center, LMU München), using established protocols. 
Procession of the raw data was kindly done by junior group leader PD Dr. Stefan 
Bauersachs. 
5.3. cDNA synthesis for qRT-PCR 
The protocol applied for cDNA synthesis was a modified version of the 
SuperScript™ First-Strand Synthesis System for RT-PCR protocol (Kit, 
#11904-018, Invitrogen, Carlsbad, CA, US). The kit also provided the standard 
reagents. 
A sample of 8.0 µl RNA (containing 4 µg total RNA) was pipetted into 250 µl 
safe-lock tubes, together with 1.0 µl of 10x Buffer and 1.0 µl of DNAseI 
(#18068-015, Invitrogen, Karlsruhe, DE). After thorough mixing (30 s), 
incubation at 25°C for 15 min was done. Then 1 µl of EDTA (25 mM) was added 
and the sample was mixed (30 s) before incubation at 65°C for 15 min. After 
chilling on ice for 1 min the sample was spun briefly and 1.375 µl of random 
hexamer primer was added, as well as 1.375 µl of dNTP (10 mM). Incubation at 
65°C for 5 min was followed by chilling on ice for 1 min.   
A mixture of reagents was added, containing (per sample): 
 10x RT buffer    2.75 µl  
 MgCl2 (25mM)   5.5 µl  
 DTT (0.1 M)    2.75 µl  
 RNAse-out    1.375 µl 
Incubation was done at 25°C for 2 min. After adding 1.375 µl Superscript II, three 
incubation steps followed: 1) 25°C for 10 min; 2) 42°C for 50 min; 3) 70°C for 
15 min. 
After chilling on ice for 1 min, 1.375 µl RNAse H (Invitrogen, Karlsruhe, DE) 
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was added, followed by incubation at 37°C for 20 min, and finally chilling on ice 
for 1 min. The cDNA was stored at -20°C. The housekeeper gene/RNA used to 
verify presence of cDNA in the samples was Gapdh. This housekeeper had been 
found not to differ much in qRT-PCR of L-Cdh1
del/del 
and L-Control (e.g. it was 
not secondarily affected by the knockout, and thus suitable) 
5.4. Quantitative RT-PCR 
Taq DNA polymerase Kit and HotStar Taq polymerase (Quiagen, Hilden, DE) 
and 96-well real-time PCR plates (Eppendorf, Hamburg, DE) were used, with 
every well contained the following: 2.0 µl of sample cDNA (diluted 1:5 with 
H2O) + 18.0 µl of Master Mix. 
Master Mix:          
10x buffer    2.0 µl 
MgCl2     1.0 µl 
dNTPs     0.5 µl 
FW primer    0.5 µl 
RV primer    0.5 μl 
Q solution    4.0 µl 
SYBRGreen (1:2000)   0.8 µl 
HotStartTaq    0.2 µl 
H2O     8.5 μl 
 
Realtime PCR was performed with a Mastercycler
®
 ep realplex PCR machine 
(Eppendorf, Hamburg, DE) using the following cycles: 
15 min 95°C (DNA denaturation) 
[begin repeatable cycle, x56] 
30 sec 95°C (DNA denaturation) 
30 sec 55°C (primer annealing) 
30 sec 72°C (elongation) 
20 sec 82°C (DNA quantification) 
[end repeatable cycle] 
15 sec 95°C (DNA denaturation) 
15 sec 60°C 
20 min continuously increasing heat to 95°C (melting curve determination) 
15 sec 95°C 
Infinite time at 4°C (cooling/storage) 
 
As fluorescent reporter, the intercalating dye SYBR
®
 Green (Lonza, Basel, CH) 
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was used to determine the melting curve. The housekeeper gene Gapdh was used 
to standardize the samples, using the Delta-CT method. Delta-Delta-CT could not 
be used to compare both groups (L-Cdh1
del/del
 and L-Control) because samples 
(mice) were not paired and there was no reason why any L-Cdh1
del/del
 sample 
should have been associated with a specific L-control sample. Therefore, both 
groups were averaged before comparing them with each other. Because CT values 
are logarithmic, adding them up and dividing by n (e.g. the sum of all samples) 
would result in geometric mean instead of arithmetic mean. To account for this, 
CT values were linearized (transformed to non-logarithmic numbers) before 
calculating the mean (e.g. arithmetic mean was calculated) as suggested in 
literature (SCHMITTGEN & LIVAK, 2008). From the means of both groups, 
fold-change of cDNA was calculated. 
The primer sequences used for qRT-PCR are listed in the “Materials” section 
(page 45).   
6. Analysis of body weight development and organ weight 
6.1. Long-term body weight development 
Mice were weighed weekly with a laboratory scale (Laboratory scale, BP4100S, 
Sartorius, Göttingen, DE). ANOVA of the data was performed with use of the 
SAS software (SAS Institute Inc., Cary, NC, US). 
6.2. Body and organ weight at specific time points 
Body weight of mice was measured before drawing of blood and section (see the 
appropriate paragraphs on necropsies). Organs were removed using pincers and 
fine scissors and placed on a special accuracy weighing machine (Laboratory 
scale, BP221S, Sartorius, Göttingen, DE). Afterwards organs were further 
processed for storage (freezing, RNAlater or formaldehyde) or discarded if not 
needed. 
7. Evaluation of serum parameters 
7.1. Blood collection 
Before section, mice were anesthetized and blood was collected from the 
retrobulbar venous plexus. Mice were killed immediately thereafter by cervical 
dislocation.  
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7.2. Serum preparation 
After leaving the blood in an eppendorf cup at room temperature for 1 hour to 
allow coagulation, spinning at 5000 rpm in a 14 cm diameter rotor centrifuge 
(Table centrifuge 5417R, Eppendorf, Hamburg, DE) forced the separation of 
serum from the solid blood components. Serum was pipetted into a new eppendorf 
cup, centrifuged again to remove any residual erythrocytes and pipetted into the 
final 1.5 ml eppendorf cup for storage in a -80°C freezer. 
7.3. Clinical chemistry 
Clinical chemistry was kindly performed by staff members of the clinical 
chemistry lab at the Campus Großhadern (Institut für Laboratoriumsmedizin, 
Klinikum der Universität München, LMU München). 
8. Induction of tumors through use of diethylnitrosamine 
(DEN) 
E-cadherin is known to be important to cell-cell-adhesion, and adhesion can be 
expected to have a great effect on tumor development. Consequently, we 
submitted our mice not only to normal conditions (“spontaneous phenotype”), but 
also to the challenge condition of a carcinogen (“phenotype after tumor 
induction”). Due to the abundancy of publications using DEN for tumor research 
(LEENDERS et al., 2008), and its ease of application, DEN was chosen as a 
carcinogen. 
A total of 92 animals were injected with DEN (early drop-outs not counted) and 
necropsy was scheduled to be performed 4, 8 or 12 months later (Table 1). 
Moribund animals were sacrificed earlier (this applied mostly to the 12-months 
group). 
 Table 1. Number of animals injected with DEN and sacrificed during the 
experiment coined “phenotype after tumor induction”. 
  
4 
months 
8 
months 
12 
months   
L-Cdh1
del/del
 11 15 20 
 
 
L-Control 12 13 21  
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8.1. Preparation of DEN and dosage 
DEN (N-Nitrosodiethylamine; Sigma, St.Louis, MC, US) was diluted in 0.9% 
NaCl solution (B. Braun Melsungen AG, Melsungen, DE) to a 1:5000 solution. 
The rubber-stopper capped bottle was protected from direct sunlight and stored at 
room temperature. While data concerning the degradation of DEN in aqueous 
solution is lacking, we precautiously refrained from using solutions older than a 
year. 
8.2. Intraperitoneal (i.p.) application 
We chose a protocol with only one injection of DEN and no additional substances 
(like barbiturate in drinking water), which are sometimes used in related 
experiments to further promote tumors (DIWAN et al., 1985; LEENDERS et al., 
2008). 
A 1-ml syringe fixed with a 30 G needle was used to inject the DEN solution 
intraperitoneally. Mice pups of 2 weeks of age were weighted and the correct 
dosis (0.025 ml/g of body weight) of DEN / 0.9% NaCl solution was drawn from 
the storage bottle (e.g. 5 µg DEN per gram of mouse body weight was applied). 
The pups were fixated at the neck with thumb and index finger while the body 
was supported by the palm of the hand, using the little finger to fixate the tail end 
of the mouse. While injecting, great care was taken to maintain the needle in the 
abdomen cavity so as not to puncture the liver or another vital organ. To 
additionally aid in this, mice were held with their head down and their tail up 
roughly at a 45 degree angle during injection to force the organs and guts away 
from the site of punctuation by gravity. 
8.3. Safety measures 
DEN is a hazardous substance and can be a danger to personnel working in an 
animal facility if inhaled (ISSENBERG & SORNSON, 1976) or incorporated via 
another route. Dangers to the personnel include cancerogenity and, to a much 
lesser extent, acute toxicity. Preparation and injection of DEN was done under a 
fume hood. Through the use of rubber-stopper capped bottles, DEN solution 
always was handled in enclosed containers until entering the animal. Before 
injection, the bench was covered with sturdy plastic foil which was later discarded 
safely to remove eventual unnoticed spills. Two pairs of nitrile gloves (AQL 1.5) 
were donned (double layer) and all materials used in direct contact with the DEN 
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were discarded with the hazardous lab waste. To prevent DEN excreted by the 
mice from contaminating the rest of the facility, mice cubs and their mothers were 
kept in separate filter-enclosed cages and were only handled by experienced 
animal caretakers (for two weeks after injection). During that time, cleaning of the 
cages was done separately from standard cleaning and all waste was also 
immediately packaged separately. 
9. Section of mice with tumors 
After noting mice body weight, mice were anesthesized and blood was gained. 
Following cervical dislocation, the abdomen was opened without contamination 
by fur. After inspection of the situs, the liver, lung and spleen were removed. 
Organ weights were noted and the lesions of the liver were classed according to 
their size and counted. From some mice of the 12-month-group, tumor tissue was 
gained for cell culture.  
The remaining mouse body with all not-paraffin-embedded organs (e.g. without 
lung and liver) was kept in 4% formaldehyde in a 50 ml falcon for possible later 
analysis of alterations (metastases etc.). 
9.1. Liver and body weight 
This was done in the same way as described for all necropsies. The liver weight 
was intended as a primary variable for some age groups (4 months and 8 months); 
and body weight was used to calculate the relative liver weight. 
9.2. Other organ weights 
Lung and spleen weight were not conceptualized as primary variables from the 
very beginning, and thus this measurement was not considered to contribute to the 
familywise error rate. Instead, documented weight alterations of these organs were 
used to fortify the observations of the primary variable (relative liver weight).  
After weighting, organs were inspected macroscopically from all sides for 
possible metastases. Alterations were documented with a camera. 
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9.3. Count of tumor lesions  
Count of tumor lesions at the livers surface is a method to quickly evaluate the 
tumor burden, but there are some difficulties:  
 a single tumor might create multiple lesions at the liver surface 
 the size of irregular formed lesions can often not be measured precisely 
 tumors sometimes can be seen, but do not breach the liver surface 
As a result measurement is very much dependent on the individual researcher, but 
can yield quite stable output if always done with the same criteria and by the same 
person. 
The liver was removed from the animal and all lobes were spread open. Lesions 
were classed (<2 mm | 2-5 mm | >5 mm) and counted. Then the liver was flipped 
over and the other side´s lesions were counted.  
9.4. Preparation of tumor samples for RNA analysis, histology and cell 
culture 
Fig. 12. Schematic of the mouse liver, 
based on “The Anatomy of the 
Laboratory Mouse” by Margaret J. 
Cook, accessible at Jax informatics. 
 
The left lobe (Fig. 12) was put into a 
histological cassette, stored in 4% 
formaldehyde in PBS and sent to the 
“Pathologisches Institut” (Universitäts 
Klinikum Heidelberg) for specialized histological analysis. A part of the median 
lobe (the part that is located adjacent to the right side of the gall bladder) was also 
stored in formaldehyde and subsequently embedded in paraffin for histological 
evaluation as a backup. The rest of the liver was processed as following: liver-
tissue that was relatively tumor-free, if available, was cut into small (roughly 
2 x 4 mm) pieces and frozen on dry ice for later storage in a -80°C freezer. If 
available, large tumors (up to 5) were separated and cleaned from healthy tissue 
and cut into two pieces. Their diameter was documented and one half was 
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prepared for paraffin embedding while the other half was stored in RNAlater® 
(Ambion [part of Invitrogen], Darmstadt, DE). 
Some tumors of the 12-month DEN group were used for generating cell lines. In 
this case, the whole necropsy procedure was done under semi-sterile conditions 
and as fast as possible. For short term storage, sterile dishes with the isolated, 
tumor-rich liver lobes were kept on ice-cold water. Large single tumors or batches 
of several smaller tumors were then removed from the liver and put into sterile 
petri dishes containing a few milliliters of DMEM/F12 cell culture medium 
(containing no “fetal calf serum” = FCS) and processed quickly, preferably in 
parallel by a second person. 
10. Establishment of long term cell culture from tumors 
The procedure was established by modifying a protocol kindly provided by 
members of the workgroup “Endokrinologische Forschung und 
Endokrinologische Ambulanz” (Medizinische Klinik und Poliklinik IV, Campus 
Innenstadt, Klinikum der Universität München, LMU München). 
10.1. Preparation of collagenase II 
The enzyme was freshly prepared prior to the necropsy. Collagenase II 
(Biochrom, Berlin, DE) was dissolved at 1.5 mg per ml of PBS. For the average 
tumor (ca. 1 cm diameter) around 10 ml of collagenase solution was needed. After 
sterile filtration (0.22 µm filter), the solution was ready for use. 
10.2. Mincing of tumors and destruction of the organ/tumor structure 
Under a sterile closed-circuit laminar flow cabinet (BDK Luft- und 
Reinraumtechnik GmbH, Sonnenbühl-Genkingen, DE), the tumors were cleaned 
of non-tumorous tissue using sterile scissors or a razor blade. Then, the tissue was 
minced thoroughly (but not too vigorously, which would have destroyed too many 
cells) in a 10 cm petri dish containing 8 ml PBS/ collagenase II solution. As a rule 
of thumb, the tissue was minced until most pieces were of roughly 0.5 mm 
diameter or less. Care was taken to use the blade in a cutting rather than a hitting 
motion to conserve cells. Cells were then transferred to a Falcon tube (50 ml). To 
maximize the yield, the petri dish was flushed with the remaining 2 ml of 
PBS/collagenase II. The falcon was placed for 50 min at 37°C on a shaking 
incubator (infors AG, Bottmingen, DE) at 110 to 220 rpm. 
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As an alternative method, the petri dish was sometimes replaced with a 50 ml 
erlenmeyer flask with wide opening. Small scissors could be inserted through the 
wide opening to mince the tumor; and the incubation was done in the same flask 
(covered with sterile aluminum foil). 
Incubation was stopped by FCS (PAA Laboratories GmbH, Pasching, AT). A 
50 ml Falcon tube filled with enough FCS to later result in a >10% FCS solution 
was fitted with a 70µm cell strainer/Falcon™ (BD, Heidelberg, DE); and the 
tumor/collagenaseII/PBS solution was pressed through the strainer with a 10ml 
glass pipette. The tube was then spun for 5 min at 1200 rpm (17 cm diameter 
rotor) and the supernatant discarded. 
10.3. Erythrocyte lyses 
The cell pellet was re-suspended in lyses buffer. The volume of buffer added was 
at least two times of cell pellet volume. Incubation was 7 min at room 
temperature. The tube was then spun for 5 min at 1200 rpm (17 cm diameter 
rotor) and the supernatant discarded. 
Buffer for erythrocyte lysis: 
 NH4Cl  0.15 M  8.29 g 
 KHCO3 1 mM   1 g 
 Na2EDTA 0.1 mM  37,2 mg 
 Add 800 ml bidistilled water 
 Set pH to 7.2 to 7.4 with HCl 
 Add bidistilled water up to final volume of 1000 ml 
10.4. Re-suspension in cell culture dishes 
Cells were re-suspended in cell culture medium DMEM/F12+10%FCS+P/S (PAA 
Laboratories GmbH, Pasching, Austria) and cultured in “BD Primaria™ 60mm 
Cell Culture Dish, surface-modified polystyrene for enhanced cell culture” (BD, 
Heidelberg, DE). 
After incubating culture dishes overnight, dishes were checked under a 
microscope (DM IL Mikroskop, Leica, Wetzlar, DE) and the medium was 
changed. Afterwards the culture was left untouched for around 3 – 4 days. 
Subsequently, cells were checked regularly and medium was changed twice per 
week. Splitting was continuously adjusted according to the proliferation rate, 
since phases of slow or no proliferation and considerable changes of the cell 
growth were to be expected in the early stages (ROHME, 1981). 
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10.5. Maintenance and splitting of cell lines 
Cells were kept in an incubator (Heraeus, Munich, DE) at 37°C and 5% CO2. For 
splitting, cultures were handled under a closed-circuit laminar flow cabinet. In 
successfully established cultures, cells had to be split one to two times per week 
with seeding of ¼ of the cells into a new dish. Cells were kept in 6-well plates, 
96-well plates, 6 cm or 10 cm dishes. 
For splitting, all reagents, buffers and media were warmed to 37°C. After washing 
with PBS, trypsin-EDTA (PAA Laboratories GmbH, Pasching, Austria) was 
added and the cells were incubated at 37°C for up to 5 min. Trypsinated cells were 
added to DMEM/F12 with FCS and centrifuged. After discarding the supernatant, 
cells were re-suspended in medium and seeded to new dishes. 
10.6. PCR of cell culture cells 
PCR of cell culture was done as described before for genotyping of mice. Instead 
of a mouse tail tip, cells of a 6 cm culture dish were scraped off and used. 
10.7. Conservation of cell-lines for future studies 
To conserve cells for later use, they were frozen in liquid nitrogen. Suspended 
cells were stored in 1.0 ml cryotubes (Nunc A/S, Roskilde, DK) containing as a 
freeze medium 400 µl DMEM + 320 µl FCS + 80 µl DMSO (PAA Laboratories 
GmbH, Pasching, AT). Cryotubes were immediately placed in a -80°C freezer for 
one night and then transferred to a tank containing liquid nitrogen for storage in 
the gas phase. 
To test whether cells were viable, a surplus tube of the batch was removed from 
the storage after a few days, placed in a 37°C water bath until liquefied and 
centrifuged for 1 min. The supernatant was discarded and the cell pellet was 
suspended in cell culture medium and seeded at 37°C and 5% CO2. 
11. Histological analysis 
Formaldehyde-fixated samples were embedded in paraffin wax and Superfrost 
slides (Themo-Scientific, Braunschweig, DE) were prepared using facilities of the 
Pathologisches Institut (Campus Innenstadt and Campus Großhadern of the 
Klinikum der Universität München, LMU München) and the Institut für 
Tierpathologie (Tierpathologie München, Tierärztliche Fakultät, LMU München). 
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Some samples were processed entirely (embedding, microtomy, H&E-staining) by 
cooperation partners (Pathologisches Institut of the Universitäts Klinikum 
Heidelberg). 
11.1. Hematoxilin and eosin (H&E) staining 
H&E staining performed by cooperation partners (Pathologisches Institut of the 
Universitäts Klinikum Heidelberg or Pathologisches Institut, Campus Innenstadt, 
Klinikum der Universität München, LMU München) was done using the 
respective institute´s procedure. H&E staining performed in our group was done 
using the following protocol:  
Slides were kept at 37°C overnight or alternatively at 50°C for one hour prior to 
the procedure. After descending ethanol series (Rothishistol → ethanol 50%), 
slides were rinsed in bidistilled water and stained in Mayer´s hematoxylin for 3-10 
min and blued in tap water for 10 min. After ascending ethanol series (water → 
ethanol 96%), eosine staining (EosinY in ethanol solution) for 5 min followed. 
After a 25 second step of ethanol and isopropanol each, the ascending ethanol 
series was continued to Rothihistol. Slides were mounted using Pertex. 
Histology reagents were acquired from the following companies: Rothihistol 
(Roth, Karlsruhe, DE); Hematoxylin (Medite, Burgdorf, DE); Eosin Y (Sigma, 
St.Louis, MO, US) Ethanol 99% with 2-Butanon 1% (HEMA GmbH & Co. KG, 
Nurnberg, DE); Isopropanol, technisch (Roth, Karlsruhe, DE); Pertex (Medite, 
Burgdorf, DE). 
11.2. Immunohistochemistry (IHC) 
After the descending ethanol series, slides were rinsed in PBS. Slides were then 
boiled in a microwave oven in citric buffer at pH 6.0 for 20 min (or 40 min if 
samples were resistant enough). Afterwards, 100 ml methanol containing ca. 
1% H2O2 (3 ml of 30% H2O2 in 100 ml) was used to block endogenous peroxidase 
activity (30 min incubation). After washing with PBS, slides were incubated with 
5% rabbit serum (PromoCell, Heidelberg, DE) in PBS for 30 min. After removal 
of serum by skidding, the primary antibody (goat vs. E-cadherin diluted 1:100 in 
PBS, #AF748, R&D Systems, Wiesbaden-Nordenstadt, DE) was incubated 1 hour 
at room temperature or 17 hours at 4°C. After washing with PBS, secondary 
antibody (Polyclonal Rabbit Anti-Goat Immunoglobulins/Biotinylated diluted 
1:200 in PBS, # E 0466, Dako, Hamburg, DE) was incubated for 1 hour at room 
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temperature. Following washing with PBS, avidin-biotin-complex (Vectastain 
Elite ABC Kit, distributed by AXXORA Deutschland GmbH, Lörrach, DE) was 
incubated for 30 min at room temperature. After washing with PBS, 
diaminobenzidine (Sigma Fast DAB Tablet Set, Sigma-Aldrich, Taufkirchen, DE) 
ready-to-use solution was applied. Time for staining varied between 5 seconds 
and 10 min, depending on the antibody used. Slides were counterstained with a 
little hematoxylin (only dipping 5 to 20 times; maximum time 1 min), blued, and 
mounted with Pertex after an ascending ethanol series. 
All of the more expensive solutions (antibodies, serum, ABC, DAB) were applied 
as drops covering just the sample on the slide. To prevent drying out, slides were 
stored in an enclosed container with high humidity. Positive control was (if 
available) a slide with a sample that was already known to react. Negative control 
was the same, but with omission of primary antibody (pure PBS used instead). 
ABC and DAB were prepared as suggested by the manufacturer(s). 
Citric buffer formula: Combine 9 ml stock solution A + 41 ml stock solution B + 
450 ml bidistilled water. Stock solution A contains 21.01 g of C6H8O7•H2O in 
1000 ml bidistilled water. Stock solution B contains 29.41 g of C6Na3H5O7•H2O 
in 1000 ml bidistilled water. 
12. Histological evaluation of HCC  
The sample processing, as well as the evaluation and quantification of 
histologically detectable focal liver lesions was kindly performed by PD Dr. 
Longerich (Research Group “Molekulare Klassifikation und neue Marker im 
HCC”, Pathologisches Institut, UniversitätsKlinikum Heidelberg). 
12.1. Histological quantification of tumors in the liver  
For evaluation of tumor areas H&E slides were digitalized using the ScanScope 
CS system (Aperio Technologies, Vista, CA, US) in combination with 
Spectrum™ management system (Aperio, version 11.0.0.725). The tumor-
occupied areas were measured using the annotation tool of the ImageScope 
software (Aperio, version 11.0.2.275). See the figure (Fig. 13) for an example. 
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Fig. 13: Using ImageScope softwares annotation tool, total liver area (pink tool) 
was measured and set into relation with tumor area (light blue tool). Large 
tumors sometimes showed necrosis, as can be seen by the destroyed area 
(histology artifact due to damaged tissue) in the largest tumor. 
12.2. Histological evaluation of tumors in the lung  
Slides from lungs of animals with HCC were stained H&E and screened for 
metastases or primary tumors by PD Dr. Longerich. 
13. Statistical analysis 
For comparing body weight gain of L-Cdh1
del/del
 vs. L-Control, 2-factorial 
ANOVA was performed using SAS software (SAS Institute Inc., Cary, NC, US).  
For all other statistical tests and for generating graphs, Prism 4.0 (GraphPad 
Software, La Jolla, CA, US) was used. All graphs show means and SEM. For 
assessing normal distribution Kolmogorov–Smirnov and/or Shapiro-Wilk 
normality test was employed if appropriate (appreciable sample size), otherwise 
normal distribution was ascertained or rejected using information from literature 
and previous experience. As suitable, t-test (two-tailed, unpaired) or 
Mann-Whitney-U test (two-tailed) was used, and confidence interval was set to 
95% (p<0.05 denoted with “*”, p<0.01 with “**” and p<0.001 with “***” in 
graphs with bars). 
 
 
 
III. Animals, Materials and Methods     45 
 
14. Primer sequences 
14.1. Primers for genomic DNA amplification 
Cdh1 (oIMR3737)   5`-CTTATACCGCTCGAGAGCCGGA-3` 
Cdh1 (oIMR3738)   5`-GTGTCCCTCCAAATCCGATA-3` 
Cre1     5`-AATCGCCATCTTCCAGCAGG-3` 
Cre2     5`-GATCGCTGCCAGGATATACG-3` 
14.2. Primers for cDNA amplification 
mMMP7_211_FW   5`-CTGCCCATGACTGGAAAACT-3` 
mMMP7_291_RV    5`-TTCTGCAACATCTGGCACTC-3` 
mScube3_128_FW   5`-ATGCCATCTGCCAGAATACC-3` 
mScube3_269_RV   5`-GGGATGTTGACACAGTCGTG-3` 
mTff2_154_FW   5`-TGCTTTGATCTTGGATGCTG-3` 
mTff2_236_RV   5`-TCCGATTCTTGGTTTGGAAG-3` 
mFxyd6_123_FW   5`-GGTGTTTGCTGTGGTCCTCT-3` 
mFxyd6_204_RV   5`-GGGCTTCTGATTGAAACTGC-3` 
mBicc1_1434_FW   5`-CATGCAGACAGAAGGCAAAA-3` 
mBicc1_1514_RV   5`-GACAGCGGACCGTATTTCAT-3` 
mAebp1_1747_FW   5`-AAGAGTTCACGAGGGCTCAA-3` 
mAebp1_1896_RV   5`-GTATTGCATGAGCAGGAGCA-3` 
mArhgap22_1285_F   5`-ATGCACACTTTGCCTGTCTG-3` 
mArhgap22_1398_R   5`-GTTCCCACCAGAGGAGATGA-3` 
mAdamtsl2_534_FW   5`-GGTTTGCGTGTCTGGAAAAT-3` 
mAdamtsl2_680_RV   5`-AGATGATTGTTGCCCTTTCG-3` 
mBex1_253_FW   5`-GTACAGAGGTTTGGGGGTGA-3` 
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mBex1_282_RV   5`-GCATGAGGCAAAACTCATCA-3` 
mGapdhFW   5’-TCATCAACGGGAAGCCCATCAC-3’ 
mGapdhRV   5’-AGACTCCACGACATACTCAGCACCG-3’ 
15. Materials 
15.1. Machines 
Accu-jet® pro pipette controller  Brand, Wertheim, DE 
Agarose gel electrophoresis chamber MWG-Biotech, Ebersberg, DE 
Benchtop 96 tube working rack  Stratagene, La Jolla, US 
Blunt forceps     Aesculap, Tuttlingen, DE 
Bulldog forceps    Aesculap, Tuttlingen, DE 
Chyo JL-200 (analytical balance)  Chyo, JP 
Chyo MJ-3000 (analytical balance)  Chyo, JP 
Curix60 Tabletop processor   Agfa HealthCare, Greenville, SC, US 
Digital Camera    Olympus, Hamburg, DE 
DM IL Flo Mikroskop+digital camera Leica, Wetzlar, DE 
DM IL Mikroskop (Cell culture)  Leica, Wetzlar, DE 
DMC-FZ30 (Digital camera)   Panasonic, Osaka, JP 
Duran®-Schott glass ware    DURAN Group, Wertheim, DE 
Electrophoresis chamber    MWG-Biotech, Ebersberg, DE 
EPS 500/400 Electrophoresis Power Supply Pharmacia Fine Chemicals, NJ, US 
Fine scissors     Aesculap, Tuttlingen, DE 
Gel documentation system   Intas, Göttingen, DE 
GeneAmp PCR System 9700   Applied Bisosystems, Foster City, US 
Glass case for glass rack   Roth, Karlsruhe, DE 
Heating plate with magnetic stirrer  IKA process equipment, Staufen, DE 
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Homogenizer Miccra    ART Labortechnik, Müllheim, DE 
Hybridization oven    H.Saur, Reutlingen, DE 
Incubator (for cell culture)   Heraeus, Munich, DE 
Laboratory scale, BP221S    Sartorius, Göttingen, DE 
Laboratory scale, BP4100S    Sartorius, Göttingen, DE 
Laminar flow cabinet    BDK, Sonnenbühl-Genkingen, DE 
Light microscope    Olympus, Hamburg, DE 
Mastercycler® ep realplex PCR machine Eppendorf, Hamburg, DE 
MicroPlate reader    Tecan, Männedorf, CH 
Microtome     Microm, Walldorf, DE 
Microwave     Siemens, Munich, DE 
Mini Protean® 3 Cell    Bio Rad, Munich, DE 
MS1 Minishaker    IKA process equipment, Staufen, DE 
Multipette® plus    Eppendorf, Hamburg, DE 
PCR-machine/thermal cycler   Biometra, Göttingen, DE 
PIPETMAN® P (1000µl)   Gilson, Limburg, DE 
PIPETMAN® P (100µl)   Gilson, Limburg, DE 
PIPETMAN® P (10µl)   Gilson, Limburg, DE 
PIPETMAN® P (200µl)   Gilson, Limburg, DE 
PIPETMAN® P (20µl)   Gilson, Limburg, DE 
PIPETMAN® P (2µl)   Gilson, Limburg, DE 
Pointed scissors     Aesculap, Tuttlingen, DE 
Power Pac 300    Bio Rad, Munich, DE 
Power Supply PPS200-1D   MWG-Biotech, Ebersberg, DE 
Rotating shaker     Infors AG, Bottmingen, DE 
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ScanScope CS system    Aperio Technologies, Vista, CA, US 
Semidry electroblotting apparatus   Bio-Rad, Munich, DE 
Spectrophotometer    Beckman, Palo Alto, US 
Table centrifuge (5417R)    Eppendorf, Hamburg, DE 
Thermomixer 5436     Eppendorf, Hamburg, DE 
Ultraschall Sonorex Super RK 102 H Bandelin, Berlin, DE 
UV-Crosslinker     Biometra, Göttingen, DE 
VakuLab s3000 (Autoclave)   MMM group, München, DE 
Watch maker forceps    Aesculap, Tuttlingen, DE 
Water bath SUB14    Grant Instruments, Royston, GB 
15.2. Consumables 
70 µm cell strainer/ Falcon™  BD, Heidelberg, DE 
96-well cell culture plates (flat-based) BD, Heidelberg, DE 
96-well real-time PCR plates   Eppendorf, Hamburg, DE 
BD Primaria™ 60 mm Cell Culture Dish BD, Heidelberg, DE 
Blotting paper       Bio-Rad, Munich, DE 
Centrifugation tube (15 ml, 50 ml)  Becton Dickinson, Heidelberg, DE 
Centrifuge tube (0.5 ml, 1.5 ml, 2.0 ml)    Eppendorf, Hamburg, DE 
Chemoilluminiscence film      GE Healthcare, Munich, DE 
CL-XPosure Film    Thermo Scientific, Rockford, IL, US 
Cover glass slides       VWR International, Darmstadt, DE 
Cryotube 1.0 ml    Nunc A/S, Roskilde, DK 
Doktorand (disposable)   LMU, Munich, DE 
Filter paper       GE Healthcare, Munich, DE 
Glass microscope slides      Menzel-Gläser, Braunschweig, DE 
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Heat sealing foil       Eppendorf, Hamburg, DE 
Heparinized capillary tubes     Brand, Gießen, DE 
Histology cassettes      Medite, Burgdorf, DE 
Multi-well cell culture plates    Becton Dickinson, Heidelberg, DE 
PCR-reaction-tubes       G. Kisker GbR, Steinfurt, DE 
Petri dishes (diameter 10 cm)     Becton Dickinson, Heidelberg, DE 
Plastic tubes (5 ml)       Greiner Bio-One, Frickenhausen, DE 
PVDF membrane       Millipore, Billerica, US 
Real-time PCR plates (96 well)    Eppendorf, Hamburg, DE 
Rundbodenröhrchen, 5 ml    Falcon/BD, Heidelberg, DE 
Standard rodent chow    Ssniff, Soest, DE 
Superfrost slides    Menzel, Braunschweig, DE 
Syringes (2, 5, 10, 20 ml)     Codan Medical ApS, Roedby, DK 
15.3. Chemicals 
2-mercaptoethanol    Merck, Darmstadt, DE 
ABC (Avidin-biotin complexes)     Vector Laboratories, Burlingame, US 
AB: donkey vs. goat AB HRP (#sc-2033) SantaCruz, Dallas, TX, US 
AB: donkey vs. rabbit HRP (#NA934V) GE Healthcare, Munich, DE 
AB: goat vs. E-cadherin, #AF748 -  R&D Systems, Wiesbaden-Nordenstadt, DE 
AB: goat vs. MMP-7  - Santa Cruz Biotechnology, Heidelberg, DE 
AB: goat vs. mouse antibody HRP  MP Biomedicals, Solon, OH, US 
AB: monoclonal mouse vs. actin (#691001) MP Biomedicals, Eschwege, DE 
AB: monoclonal rabbit vs. GAPDH (#14C10) CellSignaling, Frankfurt-Main, DE 
AB: goat vs. E-cadherin (#AF748) - R&D Systems, Wiesbaden-Nordenstadt, DE 
AB: rabbit Anti-Goat IG/Biotinylated # E 0466 - Dako, Hamburg, DE 
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AB: sheep vs. mouse HRP (#NA931V) GE Healthcare, Munich, DE)  
Acrylamide, 30%       Bio-Rad, Munich, DE 
Agarose        Invitrogen, Karlsruhe, DE 
Ammonium persulfate, 10%     Bio-Rad, Munich, DE 
Bichinonic acid    Sigma-Aldrich, Deisenhofen, DE 
BrdU      Roche, Mannheim, DE 
Bromphenol blue     Serva, Heidelberg, DE 
BSA        Roth, Karlsruhe, DE 
Calcium chloride    Merck, Darmstadt, DE 
Collagenase II     Biochrom, Berlin, DE 
CuSO4      Sigma-Aldrich, Deisenhofen, DE 
DEPC      Sigma-Aldrich, Deisenhofen, DE 
DMEM/F12 cell culture medium  PAA Laboratories, Pasching, AT 
DMEM/F12+10%FCS+P/S   PAA Laboratories, Pasching, AT 
DNA Rehydration Solution    Promega, Mannheim, DE 
DNase I Amp Grade, 1U/ µl    Invitrogen, Karlsruhe, DE 
DNase I reaction buffer, 10x   Invitrogen, Karlsruhe, DE 
DNase I, Amplification Grade  Invitrogen, Karlsruhe, DE 
dNTPs (DATP, dTTP, dCTP, dGTP) MBI Fermentas, St. Leon-Rot, DE 
DTT, 0.1 M     Invitrogen, Karlsruhe, DE 
ECL solution (#34076; #34077)   Thermo Scientific, Rockford, IL, US 
EDTA      VWR International, Darmstadt, DE 
EDTA solution, 25 mM   Invitrogen, Karlsruhe, DE 
Enzyme mix      Roche, Mannheim, DE 
Eosin Y     Sigma, St.Louis, MO, US 
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Ethanol     Merck, Darmstadt, DE 
Ethanol 99% with 2-Butanon 1%   HEMA GmbH, Nurnberg, DE 
Ethidium bromide    Roth, Karlsruhe, DE 
FCS (fetal calf serum)    PAA Laboratories, Pasching, AT 
Glacial acetic acid    Roth, Karlsruhe, DE 
Glycine   Merck    Darmstadt, DE 
HCl      Merck, Darmstadt, DE 
H2O2      Roth, Karlsruhe, DE 
Hematoxylin     Medite, Burgdorf, DE 
Hematoxylin solution according to Mayer Sigma-Aldrich, Deisenhofen, DE 
Hot-start Taq, 5 U/ µl    Quiagen, Hilden, DE 
Instant skimmed milk powder  Roth, Karlsruhe, DE 
Isopropanol p.a.    Merck, Darmstadt, DE 
Isopropanol, technisch   Roth, Karlsruhe, DE 
KCl       Roth, Karlsruhe, DE 
KH2PO4      Merck, Darmstadt, DE 
Loading dye (6x)    MBI Fermentas, St. Leon-Rot, DE 
Methanol      Merck, Darmstadt, DE 
MgCl2, 25 mM     Invitrogen, Karlsruhe, DE 
MgCl2, 25mM    Qiagen, Hilden, DE 
Molecular weight marker   MBI Fermentas, St. Leon-Rot, DE 
Na2HPO4     Merck, Darmstadt, DE 
NaCl       Roth, Karlsruhe, DE 
NaOH      Roth, Karlsruhe, DE 
Nuclei Lysis Solution    Promega, Mannheim, DE 
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PageRulerTMPrestained Protein Ladder MBI Fermentas, St. Leon-Rot, DE 
Paraformaldehyde    Sigma-Aldrich, Deisenhofen, DE 
PCR buffer with MgCl2, 10x   Roche, Mannheim, DE 
PCR buffer, 10x     Qiagen, Hilden, DE 
Pertex (mounting medium)   Medite, Burgdorf, DE 
Protein Precipitation Solution    Promega, Mannheim, DE 
Proteinase K      Roche, Mannheim, DE 
pUC mix molecular weight marker  MBI Fermentas, St. Leon-Rot, DE 
Q-Solution      Qiagen, Hilden, DE 
Rabbit serum      PromoCell, Heidelberg, DE 
Random hexamer primer    Invitrogen, Karlsruhe, DE 
Restore Western Blot Stripping Buffer Thermo Scientific, Rockford, US 
RNAlater®     Ambion (Invitrogen), Darmstadt, DE 
Rnase      Roche, Mannheim, DE 
RNase H      Invitrogen, Karlsruhe, DE 
RNaseOUT, 40 U/ µl    Invitrogen, Karlsruhe, DE 
RNeasy Mini kit      Quiagen, Hilden, DE 
Rothihistol     Roth, Karlsruhe, DE 
Roti®-Histol      Roth, Karlsruhe, DE 
RT buffer, 10x     Invitrogen, Karlsruhe, DE 
SDS        Merck, Darmstadt, DE 
Sigma Fast DAB Tablet Set   Sigma-Aldrich, Taufkirchen, DE 
Sodium citrate       Merck, Darmstadt , DE 
SuperScript First Strand cDNA Synthesis Invitrogen, Karlsruhe, DE 
Superscript III RT, 200 U/ µl   Invitrogen, Karlsruhe, DE 
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SuperScript™ First-Strand Kit  Invitrogen, Karlsruhe, DE 
SYBR® Green     Lonza, Basel, CH 
Taq DNA polymeras Kit      Quiagen, Hilden, DE 
Taq Polymerase, 5U/µl     Quiagen, Hilden, DE 
Temed        Bio-Rad, Munich, DE 
Tris      Roth, Karlsruhe, DE 
Trypsin-EDTA    PAA Laboratories, Pasching, AT 
Tween®20     Sigma-Aldrich, Deisenhofen, DE 
Vectastain Elite ABC Kit - (distributed by)  AXXORA GmbH, Lörrach, DE 
Washing buffer       Roche, Mannheim, DE 
15.4. Drugs (used on animals) 
0.9% NaCl solution    B.Braun, Melsungen, DE 
DEN (N-Nitrosodiethylamine)  Sigma, St.Louis, MC, US 
Dexamethasone       Sigma-Aldrich, Deisenhofen, DE 
Diethyl ether     Carl Roth GmbH, Karlsruhe, DE 
Histoacryl® liquid skin glue    B.Braun, Melsungen, DE 
Black ink     Pelikan, Hannover, DE 
15.5. Microarray technology 
Agilent Microarray - Agilent Technologies, Inc., Santa Clara, CA, US 
15.6. Software 
GraphPad 4.0 software   GraphPad, LaJolla, CA, US 
MicrosoftOffice2007    Microsoft, Redmond, WA, US 
OpenOffice  - Apache Software Foundation, Forest Hill, MD, US 
SAS software     SAS Institute Inc., Cary, NC, US 
Spectrum™ management system  Aperio Technologies, Vista, CA, US 
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15.7. Animals 
B6.129-Cdh1tm2Kem/J (Stock Number: 005319) Charles River, Sulzfeld, DE 
B6.Cg-Tg(Alb-cre)21Mgn/J (Stock Number: 003574) CharlesRiver, Sulzfeld, DE 
 
 
 
 
 
IV. Results     55 
 
IV. RESULTS 
1. Spontaneous phenotype of Cdh1/Alb-Cre mice 
Mice with liver-specific Cdh1 deficiency will be referred to as “L-Cdh1
del/del
”, 
while littermates with floxed, but not deleted Cdh1, will be referred to as 
“L-Control” (=can be considered wildtype mice for practical purposes). 
1.1. Generation of Cdh1 deficient mice 
Breeding of mice was successful, and offspring proved to be fertile. It was 
possible to keep the strain stable at a defined genetic distribution (both 
L-Cdh1
del/del
 and L-Control in every generation). Assuming that presence of Cre 
does not influence embryonic and early postnatal development, every generation 
should have had approximately the same number of L-Cdh1
del/del
 and L-Control 
mice. This was the case, as in the three years during the experiments a total of 147 
L-Cdh1
del/del
 and 122 L-Control was born. By a small margin, this is within the 
expected range of 118.43 to 150.57 animals of L-Cdh1
del/del
 genotype (tested with 
95% confidence interval). 
1.2. Demonstration of cre-mediated gene deletion    
 
Fig. 14. Demonstration of cre-mediated gene deletion by PCR (“M”/marker, 
“Br”/brain, “He”/heart, “Lu”/lung, “Ki”/kidney, “Mu”/muscle, “Li”/liver, 
“H2O”/negative control). DNA samples isolated from L-Cdh1
del/del
 mouse organs 
can only be amplified if a gene deletion event has occurred (Del) in the respective 
organ. Gapdh serves as a positive control. 
Organs (brain, heart, lung, kidney, muscle, liver) were collected from L-Cdh1
del/del
 
mice and genomic DNA was extracted. Forward- and reverse-primers for PCR 
were placed far too distant to each other to allow amplification of DNA unless a 
sequence between them (the floxed part of Cdh1) was missing. Marker (“M”, to 
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the left) served as verification of correct band length. As expected, a range of 
organs did not show amplification of DNA, and only liver (“Li”, to the right) did 
(Fig. 14). H2O served as negative control. Deletion of Cdh1 could thus only be 
detected in the liver, and all other organs remained unaffected. 
1.3. General assessment of the „spontaneous phenotype“ of L-Cdh1del/del 
compared to L-Control mice 
Reduction of E-cadherin in the liver had no detectable effect on mouse viability. 
L-Cdh1
del/del
 mice had slightly reduced body weight gain compared to L-Control 
(see “Long term body weight monitoring”, page 61). Neither L-Cdh1
del/del
 nor 
L-Control showed body or organ abnormalities both alive and during necropsies, 
and generally mice remained healthy until aged well over two years. No 
significantly increased incidence of tumors could be observed in the genetically 
altered mice, with only a single spontaneous liver tumor noticed within the whole 
L-Cdh1
del/del
 population in our animal facility over the course of three years. 
1.4. Expression analysis on protein level 
 
Fig. 15. Protein expression in L-Cdh1
del/del
 and L-control mice liver samples 
shown by Western blot at different ages (1 week to 48 weeks). Both E-cadherin 
and actin were reduced in L-Cdh1
del/del
. GAPDH serves as loading control. 
To confirm the loss of Cdh1 in L-Cdh1
del/del
 mice, we performed Western blot 
analysis of the liver from mice at ages 1 to 48 weeks (Fig. 15). E-cadherin in the 
liver was markedly reduced in L-Cdh1
del/del
 at 1 week and was further decreased in 
older mice. Actin behaved similarly. GAPDH served as a loading control. 
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1.5. Expression analysis on RNA level: Agilent Array 
To systematically search for genes differentially regulated by the loss of Cdh1 in 
the liver, RNA samples from mice groups aged 1 week, 3 weeks and 6 weeks 
were analysed using an Agilent array. 
In 1 week old mice some genes were 
already regulated, but the effect of 
the Cdh1 ablation was still weak (e.g. 
no statistically significant regulation of 
any RNA). In 3 week old mice a great 
number of genes was significantly 
regulated. At 6 weeks, only a select few 
genes were still regulated significantly 
(Fig. 16).   
Fig. 16. Total number of genes with significantly regulated RNA expression in 
mouse liver according to Agilent arrays in mice aged 1 week (zero genes 
regulated), 3 weeks (429 genes regulated) and 6 weeks (28 genes regulated). 
Most of the genes remaining regulated at 6 weeks of age showed stronger 
regulation at 6 weeks than it had been at 3 weeks (Fig. 17). 
Fig. 17. RNA expression 
of 10 of the most 
noticeable genes (which 
still remained significantly 
regulated in the oldest age 
group and were regulated 
the strongest) shown at 
1 week, 3 weeks and 
6 weeks. 
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1.6. Expression analysis on RNA level: qRT-PCR 
To verify the results of the Agilent arrays, qRT-PCR was done. RNA expression 
of 10 selected genes (the same genes as shown in Fig. 17) was quantified and fold 
change between L-Cdh1
del/del
 and L-Control was determined. 
Regulation of the genes shown to be regulated the strongest (and significantly) 
at 6 weeks of age could be 
verified by qRT-PCR (Fig. 18), 
and the results were mostly 
congruent with the results of the 
Agilent arrays. The fold change 
determined in qRT-PCR was 
consistently stronger than in the 
arrays for all genes.  Only minor 
alterations occurred in qRT-PCR 
compared to the arrays concerning 
the “ranking” of the genes 
regulated the strongest. 
 
Fig. 18. RNA expression in mouse liver according to qRT-PCR at an age of 
6 weeks. 
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1.7. Body and organ weight 
 
  
 
 
 
 
 
 
 
  
 
 
 
Fig. 19. Body weight (A), liver weight (B) and calculated relative liver weight (C) 
of L-Cdh1
del/del
 and L-Control mice at the indicated ages and measured during 
necropsy. Week 1: n=9+5; week 2: n=3+3; week 3: n=6+7; week 6: n=5+5; 
week 24: n=3+4; week 96; n=2+2 
Relative spleen weight (D) was not recorded from all animals at week 1 and 2. 
Week 1: n=3+3; week 2: n=3+2  
To investigate whether liver specific loss of E-cadherin affected body weight and 
organ growth, groups of mice at different ages and of both genders were sacrificed 
and body and organ weights (liver, spleen) were measured (Fig. 19). 
1.8. Serum parameters 
To search for possible effects in blood or serum caused by liver damage due to the 
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loss of E-cadherin, blood was drawn from the retrobulbar venous plexus and 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20. Blood and serum parameters of 3 months old male mice, n=4+4 in all 
graphs (A-F). 
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No significant differences between L-Control and L-Cdh1
del/del
 could be observed 
concerning several serum parameters (Fig. 20).  
Some of the above serum parameters (plus LDH, Albumin, GPT, Bilirubin) were 
also analyzed for 6 months old females (n = 3 + 4) and 1 year old females 
(n = 3 + 4). A trend separating L-Control and L-Cdh1
del/del
 was neither observed 
for single age groups nor for all age groups combined concerning any blood 
parameter (data not shown). 
1.9. Long-term body weight monitoring 
0 10 20 30 40 50 60
0.00
15
20
25
30
35
40
n=10 L-Control
n= 6 L-Cdh1del/del
Weeks
B
o
d
y
 w
e
ig
h
t 
(g
)
 
Fig. 21. Long-term weight development of L-Cdh1
del/del
 and L-Control mice 
(weekly measurement). Both groups were composed of female mice only.  
Mice were weighted weekly over the course of more than a year. A slight 
retardation of weight gain could be seen in L-Cdh1
del/del
 and 2-factorial ANOVA 
yielded Pr>F of 0.0175 for comparison of L-Cdh1
del/del
 versus L-Control (Fig. 21). 
1.10. Histology of L-Cdh1del/del vs. L-Control liver 
Previous mouse models of E-cadherin loss often showed pronounced histological 
alterations (BOUSSADIA et al., 2002; SCHNEIDER et al., 2010). We therefore 
analysed formaldehyde fixated livers histologically. 
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Fig. 22. Histological changes in the liver of L-Cdh1
del/del
 mice. (A) H&E and 
(B) Elastica van Giesson staining of livers slides showing a periportal field (age 
of mice: 5 weeks). L-Cdh1
del/del
 mice are characterized by alterations around the 
small bile ducts. (C) Immunohistochemistry showing E-Cadherin localization in 
mouse liver (age: 6 weeks). Control mice display normal distribution of the 
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protein, with small amounts around the central vein (CV) and higher amounts 
around the periportal fields (PPF). In L-Cdh1
del/del
, E-Cadherin is considerably 
reduced, but residues remain (white arrows). Black bars on all slides: 200 µm. 
Histologically, L-Cdh1
del/del
 livers differed from those of L-Control mice. 
Alterations of periportal fields consisting of cell proliferation mostly around the 
small bile ducts (part of the Glisson-Trias) could be seen in H&E-stained liver 
sections of L-Cdh1
del/del 
(Fig. 22 A). The alterations were even moreeasy to notice 
when EvG staining was used (Fig. 22 B). Collagen (stained red) accumulation 
seemed to be a component of the lesions. The alterations appeared periodically in 
mice of all ages with certain fluctuations. While Fig. 22 shows alterations of a 
periportal field typical for L-Cdh1
del/del
, not all periportal fields of L-Cdh1
del/del
 
mice had alterations of that intensity.  
There seemed to be a trend toward more pronounced alterations in younger mice 
(aged around 5 weeks), but this could not be proven definitively. 
Immunohistochemistry confirmed the loss of E-cadherin in L-Cdh1
del/del
 livers 
(Fig. 22 C). 
2. Phenotype after tumor induction 
The carcinogen DEN was injected in groups of male mice at an age of 2 weeks to 
induce HCC. 
2.1. General assessment of the „phenotype after tumor-induction“ of 
L-Cdh1
del/del
 compared to L-Control mice 
All mice, regardless of their genotype, developed tumors after injection of DEN. 
Eight months after tumor induction, tumors were always visible on the liver 
surface to the naked eye. If mice were kept longer than 8 months, they sooner or 
later fell ill (e.g., 100% of mice developed tumors) and had to be euthanized, if 
symptoms were so pronounced that they fulfilled the termination criteria. The 
typical symptoms of progressed stages of liver tumor included:  
- an enlarged mass in the abdomen (visible and/or palpable) 
- decreased activity of the mouse 
- in some cases icterus (visible on ears and pads) 
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During necropsies, alterations of the liver were frequently obvious (Fig. 23 A). 
Occasionally, tumorous alterations of the lung were noticed (Fig. 23 B).  
Histological examination revealed most of those not to be metastases but primary 
lung tumors (being identified mostly as adenocarcinoma) induced by DEN away 
from the main site of pharmacological action (Fig. 24). Concerning lung tumors or 
metastases, no significant difference between L-Cdh1
del/del
 and L-Control was 
detected (data not shown). At necropsy, no visible tumors could be detected in 
other internal organs or the carcass. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 23. Necropsy of mouse with tumors. 
(A) Icteric mouse. Pronounced tumorous alterations of the liver (white arrow) as 
well as a yellowish touch on the hairless outer skin and in the opened situs (black 
arrows) can be seen. 
(B) Conspicuous alteration of the lung (thin white arrow) during necropsy. A 
subsequent histological examination did not detect liver metastases, the alteration 
probably being caused by a primary lung tumor instead (adenocarcinoma). 
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Fig. 24: Histology of several tumors and/or secondary alterations of the lung. The 
alterations are most probably primary tumors of the lung and not metastases 
originating in the liver. 
2.2. Histological nature of DEN-induced tumors in the liver 
 
 
 
 
 
 
 
 
 
Fig. 25. A variety of HCC forms could be induced in livers of both L-Cdh1
del/del
 
and L-Control mice by DEN. Cancer staging was done, and tumors reaching G3 
could be found in both genotypes. G4 was diagnosed only a single time in a 
Cdh1
del/de
. 
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Histological examination confirmed that the tumors in the liver were chiefly 
HCCs. Often, a multitude of isolated different tumor nodes could be seen and the 
HCCs had a broad spectrum of (loss of) differentiation. Stages G1 to G3 could be 
found in mice of the 8 month group and older (Fig. 25), while in mice 4 month 
after DEN only dysplastic foci were found. 
2.3. Body and organ weight 
Organs of mice were weighted during necropsy four months (Fig. 26), eight 
months (Fig. 27) and twelve months (Fig. 28) after induction of tumors with DEN. 
Four months after DEN: 
 
 
 
 
 
 
 
 
 
 
Fig 26. Body weight (A) and relative weight of liver (B), lung (C) and spleen (D) 
during necropsy of mice 4 months after tumor induction by DEN. 
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Eight months after DEN: 
 
 
 
 
 
 
 
 
 
 
 
Fig 27. Body weight (A) and relative weight of liver (B), lung (C) and spleen (D) 
during necropsy of mice 8 months after tumor induction by DEN. 
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Twelve months after DEN (some mice euthanized prematurely): 
 
 
 
 
 
 
 
 
 
 
 
Fig 28. Body weight (A) and relative weight of liver (B), lung (C) and spleen (D) 
during necropsy of mice 12 months after tumor induction by DEN. Some mice 
were euthanized up to 4 months before reaching that age. 
Data was analyzed with unpaired, two-tailed t-test and, if normal distribution 
could not be assumed, additionally with Mann-Whitney-U test 
(Mann-Whitney-Wilcoxon = MWW). The differences between L-Cdh1
del/del
 
vs. L-Control liver, lung and spleen weights were significant (or even highly 
significant) at 8 and 12 month after DEN injection, while at 4 month there was a 
trend but not a significant difference yet.  
Lung and spleen weight were never intended as primary objectives (primary 
variables) in this experiment. The main purpose of showing these records is to 
reinforce the data on the liver alterations (caused by HCC), since increased spleen 
weight correlates with HCC (OH et al., 2003) and alterations of the lung are also 
associated with liver failure (MACHICAO & FALLON, 2012). Since the 
variables are corroborating the single primary objective by being interdependent 
with it, instead of being primary objectives themselves, adjustment of confidence 
interval by Bonferroni correction might be excessive. Nonetheless, if Bonferroni 
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or Bonferroni-Holm correction (VICTOR et al., 2010)  is applied to adjust 
confidence intervals (for 3 hypotheses:  relative liver, lung and spleen weight), the 
data remains significant for all relative organ weights of the 8 and 12 months age 
groups. 
2.4. Macroscopical tumor count 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29. Lesions counted on the liver surface at 4 (A), 8 (B) or 12 (C) month after 
DEN injection. Some mice of the oldest group (C) were euthanized before 
reaching the planned age. 
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Tumor lesions visible on the liver surface were categorized into three size classes 
and counted (Fig. 29). Groups of 4 and 8 months had normal distribution and 
t-test was used. The 12 months group did not show normal distribution and 
Mann-Whitney-U test was applied. 
In all age groups, the total lesion number is increased in L-Cdh1
del/del
 mice 
compared to L-Control animals, and especially lesions > 5 mm were eye-catching 
in the 8 and 12 month groups. 
2.5. Histological tumor count 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30. Tumorous alterations on liver slides (circled with yellow line). 
 
Fig. 31. Histologic evaluation of liver 
tumors. Mean tumor area on liver slides 
of L-Cdh1
del/del
 and L-Control eight 
months after tumor induction by DEN.  
Histologically, L-Cdh1
del/del
 livers 
showed larger and/or more tumors on 
slides (Fig. 30). A statistical evaluation showed striking, but not significant 
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differences (Fig. 31). Mann-Whitney-Wilcoxon test (p = 0.0628) was used to 
evaluate significance (because normal distribution could not be ascertained). 
2.6. Survival curve 
 
 
 
 
 
 
 
Fig. 32. Kaplan-Meier plot of mice originally scheduled for necropsy 12 months 
after DEN injection. 
If kept longer than 8 months after DEN injection, mortality was higher in 
L-Cdh1
del/del
 compared to L-Control (Fig. 32). Mice were euthanized if the 
termination criteria as specified for this experiment were reached. At 12 months, 
all remaining mice were euthanized as well. At that point, 81% of L-Control mice 
were still alive, compared to only 30% L-Cdh1
del/del
.  
3. Establishment of primary cells  from tumors  
For use in future projects aiming at investigating the molecular mechanisms 
underlying the function of E-cadherin in liver tumorigenesis, we generated 
permanent cell lines. Tumors were harvested from L-Cdh1
del/del
 and L-control 
mice 12 months after chemically inducing the tumors with DEN. 
Cell cultures isolated from animal tissue can be kept alive for some time and cells 
can proliferate even if they stem from normal, unaltered tissue. Normal 
mammalian cells have a limited capability to proliferate, though. At some point 
they will stop dividing and the cells will stagnate or die. In contrast, we isolated 
cells from tumors in the hope that permanent cell lines could be created. To prove 
that permanent cell lines were established, we split the cultures more often than it 
should have been possible with “normal” mouse cells. We could maintain some 
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cell cultures for several months with weekly or biweekly splitting, resulting in 
20 or more successful passages. The cells therefore had surpassed the hayflick 
limit (number of possible cell divisions) of about 8 to 11 expected for typical adult 
mouse cells (ROHME, 1981). After it was clear that the cell morphology 
remained stable and homogenous, it was assumed that permanent and mostly 
single-clone cell lines had been achieved.  
 
 
 
 
 
Fig. 33: cell lines which turned out to have long-term split potential. (A) Cell line 
“145” was derived from a L-Cdh1
del/del
 mouse (photo 3 months after tumor 
harvest). (B) Cell line “118” was derived from L-Control mouse (photo: 5 months 
after tumor harvest), cells at that time still showed a somewhat heterogeneous 
outlook. The names of the cell lines were derived from the respective donor 
mouse` s number. 
Around a dozen lines could be kept for an extended period of time (some were 
subclones of each other). With some lines it was unclear whether they had already 
surpassed the hayflick limit or not, and some were contaminated with fibroblasts. 
One line derived from L-Cdh1
del/del
 and one line derived from L-Control were 
chosen for prolonged cultivation and permanent storage: cell lines “118” and 
“145” (Fig. 33). 
“118” was kept for around 7 months (of that, at least 4 month with regular 
splitting twice per week with 1:4 dilutions) and “145” was kept 5 months (with at 
least 2 months of regular splitting twice per week with 1:4 dilutions). Afterward, 
the cells were frozen in liquid nitrogen for storage. 
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3.1. Cdh1 PCR of cell culture cells 
 
Fig. 34. PCR of cell culture performed similar to tail clip genotyping. “34 Liver” 
is normal mouse liver tissue and “DLD1” is a human-derived cell culture (used to 
test whether non-mouse cells could give a signal in this PCR). “+POS” is a 
mouse L-Cdh1
del/del
 tail tip and “-NEG” is bidistilled water. All other samples are 
from cell lines stemming from mouse liver tumors, and the number denotes the 
animal`s number from which they were derived. “51”, “145” and “159” were 
L-Cdh1
del/del
 mice, while “52” and “118” were L-Control mice. Presence of a 
Cdh1 signal does not necessarily exclude the possibility of successful knockout, 
but it proves that at least some of the cells in the population are derived from cells 
that had been unaffected by Cre in the living animal. Only type “145” cell lines 
(L-Cdh1
del/del
) show complete loss of Cdh1 positive cells. 
PCR of cell material was done as described previously for routine genotyping of 
mice. The forward primer utilized had a binding site in exon 10 of Cdh1, which 
should be missing on successful Cre-mediated recombination. Therefore, loss of a 
signal meant that all cells in the cell population did not possess a functional Cdh1 
gene (or that either reverse or forward primer site had been altered beyond 
recognition due to direct DEN action or alterations caused by tumor 
transformation). 
While the Cdh1 PCR product was, as expected, detected in all cells derived from 
L-Control, it also was present in most L-Cdh1
del/del
 cell lines (Fig. 34). Only cells 
of the “145” type did not show a Cdh1 signal in the PCR. 
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V. DISCUSSION 
The aim of the project was to investigate E-cadherin (TAKEICHI, 1990) effect on 
physiology and pathophysiology of the liver. Special focus was E-cadherin effects 
on HCC, which is important to human medicine (JEMAL et al., 2011). To this 
end, we generated liver specific E-cadherin deficient mice using the Cre-Lox 
system (SAUER, 1987). A group of mice was injected with the chemical 
carcinogen DEN (LEENDERS et al., 2008). 
1. Spontaneous phenotype 
The protein E-cadherin is known to be essential in many organs. Despite this, 
liver-specific deletion of Cdh1 using a cre/loxP system did not significantly affect 
mouse development or health, and only the impact on postnatal growth was 
significant (although even here the effects are modest). Single age groups 
occasionally showed coincidental differences between L-Control and L-Cdh1
del/del
 
organ weight, but due to the high number of age groups and parameters tested, 
this can be assumed to be the result of random events (VICTOR et al., 2010). No 
consistent trend separating control from L-Cdh1
del/del
 liver weights was observed. 
Other organ weights (spleen) did not show a consistent trend separating the two 
groups, either. In conclusion, L-Cdh1
del/del
 were indistinguishable from L-Control 
mice during necropsies and no conspicuous organ abnormalities were detected 
macroscopically in any genotype. 
This is especially surprising since other models of organ-specific E-cadherin 
ablation in organs like intestine (SCHNEIDER et al., 2010) or mammary gland 
(BOUSSADIA et al., 2002) have had severe effects on animal health. 
Three hypothesis can be formulated to explain this observation: 
1) The loss of Cdh1 is restricted to a limited number of cells (less than 100% 
of the tissue) in our model 
2) E-cadherin is not essential for the liver under normal conditions 
3) The liver has a mechanism to compensate for E-cadherin loss 
Possibly a combination of the above is true. 
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The cre/loxP system is known to affect only a part of the cells in experimental 
animals. Some analyses have indicated that the percentage of affected target cells 
in a number of conditional knockout models does not surpass 40% (METZGER & 
CHAMBON, 2001). The group that originally developed the Alb-Cre mouse, 
which was used in our experiment, claimed a 90% efficiency of gene 
recombination after an onset time of around 6 weeks (POSTIC & MAGNUSON, 
2000). The absolute evaluation of the recombination efficiency is difficult, 
because the organ contains target cells (hepatocytes in this case) and a significant 
amount of non-target cells (connective tissue, blood cells, endothelial cells of the 
blood vessels, etc.) which might or might not “contaminate“ the samples with 
expressed protein. We could show that L-Cdh1
del/del
 lost a considerable amount of 
E-cadherin in the liver, using qRT-PCR (fold change of 0.1669 for Cdh1 RNA 
in 6 week old mice) and Western blot analysis (only minor amounts of E-cadherin 
detectable in mice older than 3 or 4 weeks). Actin, often used as a loading control 
in Western blot, turned out to be also decreased. There is a known relationship 
between the two proteins (NELSON, 2008), and the reduced actin levels 
demonstrated that E-cadherin loss in our model did have an effect on associated 
proteins. According to the manufacturer the antibody does not bind a specific type 
of actin, instead binding an epitope conserved in all actins. In light of this result, 
we employed GAPDH as a loading control. 
While an absolute quantification (in %) is difficult using IHC, we could show that 
E-cadherin immunostaining in L-Cdh1
del/del
 liver was reduced, albeit some 
E-cadherin positive cells always remained (sometimes concentrated in pockets 
and sometimes single).  
Unlike organs in which E-cadherin has been shown to be crucial (skin, intestine), 
the liver might not be under a severe mechanical stress. Shear stress and other 
forms of physical strain are possibly lower in an organ like the liver. The liver 
architecture is significantly different from the epithelial layers in organs like the 
skin. The liver parenchyma cells are not packed tight like epidermal skin cells, for 
example, but are rather optimized for maximum contact with the blood flowing 
through the liver (BRAET & WISSE, 2012). The liver parenchyma cells are 
possibly less dependent on a firm connection with their surroundings, in 
comparison with skin or intestine cells. The fact that the liver is more vulnerable 
in the case of blunt trauma, compared to other internal organs (POP et al., 2012), 
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could hint to it having an architecture not optimized for resisting mechanical 
stress (and thus likely not requiring high shear stress resistance under 
physiological conditions). 
There are several ways how the liver could compensate E-cadherin loss. Another 
cadherin or pseudo-cadherin could replace E-cadherin (e.g. a related protein takes 
over the function of E-cadherin). Albeit we could not show significant increase of 
any member of the cadherin family using RNA arrays, this explanation is still not 
too far-fetched. The cadherin family is huge and possibly not all members have 
been identified yet. Consequently, a few of the more exotic cadherin members 
might be missing on contemporary RNA arrays like the Agilent Array that we 
employed. Another way to compensate conditional ablation of E-Cadherin could 
be regeneration and replacement of damaged cells. The liver is known to be 
capable of impressive feats of regeneration (BOOTH et al., 2012; GENTRIC et 
al., 2012). Liver stem cells („oval cells“) are located closely to the periportal 
fields (FAUSTO & CAMPBELL, 2003),  and they could replace failing hepatic 
cells (e.g. cells with induced recombination) quickly. Such stem cells are almost 
surely not affected by the recombination (the albumin promoter is probably not 
yet activated) until they have differentiated into functional liver parenchyma cells. 
The liver therefore could possibly provide a constant stream of (yet not 
E-cadherin deficient) replacement cells. This peculiar effect is due to the nature of 
the model we employed, with Cre production being dependent on an activation of 
regions which are probably dormant in stem cells. Other models, where Cre is 
produced in all cells regardless of them being stem cells or not, will likely behave 
different. 
Both histology and RNA array results suggested that the L-Cdh1
del/del
 knockout 
mice were affected the most at a young age (around 3-5 weeks). Agilent arrays 
showed that some genes were strongly and significantly regulated on RNA level 
in L-Cdh1
del/del
 mice liver at 6 weeks, generally increasing the fold change with 
age. Interestingly, a large amount of genes was statistically significantly regulated 
at 3 weeks, while at 6 weeks only a few genes were regulated (but those were the 
genes regulated strongest). A qRT-PCR could confirm the strong regulation of 
selected genes at 6 weeks of age in L-Cdh1
del/del
. This RNA and histology 
observations could point to remodeling processes, where the animal copes with 
the loss of E-cadherin. Afterwards, the animal has established a permanent 
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compensation mechanism by employing alternative proteins to E-cadherin and/or 
by supplying a constant stream of replacement cells for maintaining the liver 
parenchyma. Of course this could in some way hamper postnatal development, 
which would explain the weight differences between L-Cdh1
del/del
 and L-Controls. 
Aside from the slight weight difference, the animals health was virtually 
unaffected by the Cdh1 recombination. 
Probably all three hypotheses are true to a certain extent: the liver is an organ 
known for most impressive regeneration of lost cells and thus can probably 
compensate the incomplete (less than 90%) loss of a protein easily after an 
adaption and remodelling phase (upregulating certain genes for compensatory 
mechanisms), especially since it likely is under less physical strain compared to 
organs like the intestine. Consequently, liver homeostasis is affected much less by 
organ-specific E-cadherin depletion than originally expected. 
2. Phenotype after tumor induction 
Liver specific deletion of Cdh1 altered the susceptibility to chemically (DEN) 
induced liver tumorigenesis. Four months after DEN injection, tumors were 
already visible on the liver surface of a few L-Cdh1
del/del
, while tumors were never 
seen in the livers of control mice (although small pre-cancer nodes could be seen 
histologically in both groups). Both control and L-Cdh1
del/del
 mice developed liver 
tumors at the age of 12 months, but the latter reached moribundity faster. 
Because mice were still only weakly affected by the carcinogen four months after 
DEN and mice kept for a longer time often did not even reach an age of 12 month, 
those age groups (4 and 12 months) were suboptimal for measurement of certain 
tumor effects. Thus, we can conclude that mice 8 months after DEN injection are 
the best suited to evaluate quantitative effects of conditional E-cadherin loss on 
the progress of DEN-induced liver tumorigenesis.  
Parameters like body weight, relative liver weight and number of tumor lesions at 
different ages were evaluated. The total number of macroscopically visible lesions 
was increased, and lesions also reached larger maximum diameters in 
L-Cdh1
del/del
. Using digitalized slides, the histological tumor area was found to be 
significantly higher in L-Cdh1
del/del
 compared to L-Control mice. This increased 
tumor burden in L-Cdh1
del/del
 was probably the main factor contributing to the 
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increased liver weight.  
The conclusion that can be drawn from the development of tumors in L-Cdh1
del/del
 
compared to L-Control is that the lack of the functional Cdh1 gene enables tumors 
to grow faster. This could have several reasons. 
1) Liver cells lacking Cdh1, when mutated by DEN, become more 
aggressive, faster-growing, tumor cells. 
2) The genes upregulated to compensate for E-cadherin loss enable tumor 
cells to be more aggressive. A previous study has, for example, correlated 
elevated matrilysin (MMP) with more aggressive tumors 
(GROBLEWSKA et al., 2012). 
3) More cells become tumor cells, because less or minor mutations are 
sufficient to convert a Cdh1-defficient cell to a tumor cell (compared to 
L-Control cells). The increased growth is thus a pseudo-gain in speed: the 
higher total amount of tumors consequently leads (if Gaussian/normal 
distribution is assumed) to more outlier super-fast growing tumors. Those 
outliers overgrow and obscure the presence of the normal-speed tumors. 
4) Tissue lacking E-cadherin is not that resistant to tumor invasion and the 
tumors in the E-cadherin deficient liver can grow more easily. 
The first two of the hypotheses stated (or a combination of both) sound the most 
plausible, because there is an abundance of  studies pointing to a connection of 
tumor aggressiveness with Cdh1 loss (in the tumor cells) or upregulation of 
certain proteins like matrilysin (MATSUMURA et al., 2001; CHIEN et al., 2011; 
GROBLEWSKA et al., 2012; KUMAR et al., 2012). In summary, we could show 
that in a mouse model of liver specific E-cadherin loss, HCC induced by a 
carcinogen is more agressive. These findings prove that Cdh1 acts as a tumor 
suppressor gene in the liver, matching the results from literature which have 
shown Cdh1 relevance for tumors concerning other organs.  
3. Cell culture permanent lines 
Mammalian cells are known to have a limited split potential (hayflick limit), but 
in contrast to many other mammalian cells, cultured mouse cells (from non-
tumorous tissue) are notorious for spontaneous transformation into permanent cell 
V. Discussion    79 
 
lines (ROHME, 1981). In addition, primary liver cell cultures are known to face 
the problem of fibroblasts overgrowing the cells of the intended cell type 
(WEINSTEIN et al., 1975). Those fibroblast or other non-hepatic cells present 
might become permanent cell lines through spontaneous transformation, despite 
their originally non-tumorous nature. 
It is therefore not easy to prove that the cells that we cultured are really of the 
intended cell type (HCC cells), or whether they are liver parenchyma cells at all. 
The only cells where HCC origin (or at least liver parenchyma origin) can be 
assumed as very likely are the cells in which no Cdh1 could be detected in PCR 
(assuming that the destruction of forward or reverse primer site due to random 
mutations or chromosome aberrations caused by spontaneous transformation is a 
rare event). Those cells therefore can be presumed to be originally liver cells, 
because only liver parenchyma cells produce albumin, and consequently in our 
model also Cre (which in turn leads to partial Cdh1 deletion and loss of exon 10 
and thus, the site for the forward primer). The “145” cell line fulfilled the 
necessary criteria (PCR using Cdh1-specific primers did not yield a product) and 
can be considered to be a HCC permanent cell line without contamination by 
other cells (like fibroblasts, for example). 
The “145” line proved stable, and the cells did survive storage in liquid nitrogen 
(at least for short periods of time) and can be assumed to be of HCC origin. The 
cell line therefore has the potential to be used, for example, in subsequent projects 
investigating the molecular mechanisms underlying the function of E-cadherin in 
liver tumorigenesis. 
4. Considerations for future projects 
Finally, in light of the good correlation between liver weight and tumor burden 
8 months after DEN, for future projects the liver weight may be considered a good 
primary variable for similar experiments (instead of the often-used tumor lesion 
count). Weight is much easier to measure than other tumor parameters and the 
standardization is better in case of several different scientists or technicians doing 
the measuring. Also, statistics with organ weights are easier to handle than those 
with classed variables (like tumor lesion size classes). On the downside, some of 
the more complex information could be missed if only liver weight is gained. 
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VI. SUMMARY 
This work employed a mouse model of liver specific depletion of the gene Cdh1 
and its respective protein E-cadherin to study the role of this protein in liver 
homeostasis and pathophysiology. The experiment was done with specific focus 
on the effects concerning hepatocellular carcinoma (HCC) development. 
Background: Cadherins are present in all higher organisms, and have been 
studied rigorously in the past. The cadherin family is huge, encompassing more 
than 400 (known) members. E-cadherin is the name-giver of that family and is 
considered to be of great importance to a broad range of physiological and 
pathophysiological functions. Known functions include cell-cell adhesion and 
deregulation of E-cadherin (in almost all cases a down-regulation) is associated 
with increased aggressiveness in both human and animal tumors. Aside from that, 
E-cadherin is of great importance during embryogenesis. 
Worldwide, HCC is an important disease in humans, especially in certain 
countries (mostly developing countries). While females are only occasionally 
affected by HCC, it ranks among the top 3 tumor-related death causes in males. 
The difficulties in treating this tumor curatively make research of genes or 
proteins relevant to HCC important for human medicine improvement. The 
existence of a connection between Cdh1 or E-Cadherin and HCC has been 
suggested, but more research is still required. 
Methods: Employing Cre/loxP technology, a mouse model of liver specific 
E-cadherin depletion was created (L-Cdh1
del/del
). The mice were compared to 
littermates with normal Ecadherin levels (L-Control). Mice body and organ 
weight was documented at different ages, and liver tissue was analyzed using 
qRT-PCR (cDNA), Western blot, histochemistry and immunohistochemistry. 
To test effects of the reduced E-cadherin on tumor development, a cohort of male 
mice was injected with a chemical carcinogen (DEN) at two weeks of age to 
induce HCC, and mice were analyzed 4, 8 or 12 months later. 
Results: Aside from a slight retardation in weight gain, L-Cdh1
del/del 
did not suffer 
from severe health effects or spontaneous tumor development. Histology showed 
some alterations around the small bile ducts in the liver (in the periportal fields) 
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and RNA analysis showed that mice underwent a phase of considerably altered 
RNA activity (429 significantly regulated genes at 3 weeks of age), but later only 
a few up/down-regulated genes remained (28 genes at 6 weeks of age). Aside 
from Cdh1, no genes considered cadherin family members were regulated. 
Western blot analysis, qRT-PCR and IHC confirmed that E-cadherin was 
down-regulated on RNA level and on protein level in this animal model. 
All mice injected with DEN developed tumors, but L-Cdh1
del/del
 were affected 
more heavily, with tumors reaching large diameters faster. If mice were kept 
longer than 8 months, L-Cdh1
del/del
 had to be euthanized significantly earlier than 
L-Control. 
A spin-off of the model was the establishment of a permanent cell line, developed 
from a liver tumor of a L-Cdh1
del/del
 mouse. PCR requiring a functional primer 
binding site on exon 10 of Cdh1 could not produce DNA product, indicating that 
the cell line was a derivative of an E-cadherin negative liver cell. 
Conclusion: Liver specific E-cadherin reduction had a surprisingly small effect in 
the present mouse model (compared to the effects of E-cadherin loss in organs 
like the skin or intestine, as documented in the literature) if mice were not 
challenged with a chemical carcinogen.  
If mice were challenged with experimental HCC induction, lack of E-cadherin had 
a strong effect on the tumor growth. These findings attest, by an experimental 
animal model, the importance of E-cadherin for tumor development in the liver. 
This data reinforces previous observations concerning E-cadherin effects on 
tumors in studies working with resected human tumors of the liver or with 
conditional organ specific mouse models studying carcinoma in other organs (like 
the mammary gland, for example). Therefore, this animal model could help 
improve the understanding of mechanisms regulating aggressiveness in human 
tumors. 
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VII. ZUSAMMENFASSUNG 
Für diese Arbeit wurde ein Mausmodel mit leberspezifischem Ausfall des Gens 
Cdh1 und des entsprechenden Proteins E-cadherin genutzt, um dessen Bedeutung 
in der Homöostase und Pathophysiologie der Leber zu untersuchen. In diesem 
Experiment wurde dabei besonders viel Wert auf die Effekte gelegt, welche die 
Entwicklung von Hepatozellulärem Karzinom (HCC) betreffen. 
Hintergrund: Cadherine gibt es in allen höheren Organismen, und an ihnen 
wurde bereits intensiv geforscht. Die Cadherin Familie ist zahlreich und umfasst 
mehr als 400 (bekannte) Proteine. E-cadherin, das ursprünglich namensgebende 
Protein der Familie, wird mit einer großen Bandbreite an Funktionen in 
Physiologie und Pathophysiologie assoziiert. Bekannte Funktionen umfassen den 
Zell-Zell-Zusammenhalt, und eine Deregulation von E-cadherin (in fast allen 
Fällen eine Herabregulation) wird mit einer vermehrten Aggressivität von 
Tumoren in Zusammenhang gebracht. Abgesehen davon hat E-cadherin auch 
noch große Bedeutung in der Embryogenese. 
Weltweit ist HCC eine wichtige Erkrankung des Menschen, speziell in 
bestimmten Ländern (sogenannten “Entwicklungsländern”). Frauen sind zwar 
verhältnismäßig selten davon betroffen, aber unter Männern nimmt HCC einen 
der drei Spitzenplätze ein was (Tumor-assoziierte) Todesursachen angeht. Die 
Schwierigkeiten diesen Tumor kurativ zu behandeln, bedingen dass Forschung an 
Genen oder Proteinen mit Bedeutung für HCC von Wichtigkeit für eine 
Verbesserung der Humanmedizin ist. Dass eine Verknüpfung zwischen 
Cdh1/E-Cadherin mit HCC besteht ist bereits bekannt, dennoch ist eine 
gründlichere Forschungsarbeit notwendig. 
Methodik: Unter Benutzung der Cre/loxP  Technologie wurden Mäuse mit einem 
leberspezifischem Verlust von E-cadherin generiert (L-Cdh1
del/del
). Die Mäuse 
wurden mit Wurfgeschwistern mit normalen E-cadherin Status (L-Control) 
verglichen. Körper- und Organgewicht wurde zu mehreren Zeitpunkten gemessen, 
und Lebergewebe wurde mit qRT-PCR (cDNA), Western blot, Histochemie und 
Immunhistochemie untersucht. 
Um den Effekt von reduziertem E-cadherin auf die Tumorentwicklung zu testen, 
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wurde eine Gruppe männlicher Mäuse im Alter von zwei Wochen mit einem 
chemischen Karzinogen (DEN) behandelt um HCC zu erzeugen. Die Mäuse 
wurden 4, 8, oder 12 Monate später untersucht. 
Ergebnisse: Abgesehen von einer leicht verringerten Gewichtszunahme waren 
L-Cdh1
del/del 
gesundheitlich weitestgehend unbeeinflusst durch den E-cadherin 
Verlust. Histologisch waren jedoch einige Veränderungen an/um die feinen 
Gallengänge (im Periportalfeld) zu erkennen. Eine Messung der RNA ergab, dass 
die Mäuse eine Phase erheblich veränderter RNA Aktivität durchlaufen 
(429 signifikant regulierte Gene im Alter von 3 Wochen), aber nicht viele dieser 
Gene bleiben längerfristig hochreguliert (nur noch 28 im Alter von 6 Wochen). 
Abgesehen von Cdh1 war kein Mitglied der Cadherin Familie auf RNA Ebene 
signifikant reguliert. Mit Hilfe von qRT-PCR, Western Blot und IHC konnte 
bewiesen werden, dass E-cadherin in diesem Tiermodell auf RNA und auf Protein 
Ebene herabreguliert ist. 
Alle mit DEN injizierte Mäuse entwickelten Tumore, aber L-Cdh1
del/del
 Mäuse 
waren stärker betroffen. Hier erreichten Tumore bereits früher große 
Durchmesser. Wenn Mäuse länger als 8 Monate nach Karzinogengabe gehalten 
wurden, mussten L-Cdh1
del/del
 signifikant früher euthanasiert werden als 
L-Control. 
Ein Nebenprodukt dieses Models war die Etablierung einer permanenten Zelllinie 
aus der Leber einer L-Cdh1
del/del
 Maus. Eine PCR, welche eine funktionierende 
Primer Bindungsstelle auf Exon 10 des Cdh1 Gens benötigt, konnte kein DNA 
Produkt vermehren. Dadurch konnte bewiesen werden, dass die etablierte 
Zelllinie ein Abkömmling einer E-cadherin negativen Leber Zelle war. 
Schlussfolgerung: Leberspezifischer Verlust von E-cadherin hat einen 
überraschend schwachen Effekt in einem Mausmodel (verglichen mit dem aus der 
Literatur bekannten Effekt von E-cadherin Verlust in Organen wie z.B. Haut oder 
Darm) solange die Mäuse nicht mit einem weiteren Faktor (einem Kanzerogen) 
konfrontiert werden.  
Litten die Mäuse an HCC, so hatte der Mangel an E-cadherin einen starken Effekt 
auf das Tumorwachstum. Dies ist ein tierexperimenteller Beweis für die 
Bedeutung von E-cadherin für Tumorentwicklung in der Leber. Das Ergebnis 
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bestätigt frühere Erkenntnisse betreffs des Zusammenhangs zwischen E-cadherin 
und Tumoren, welche an resezierten Lebertumoren aus der Humanmedizin und 
anhand von anderen konditionalen E-cadherin defizienten Mausmodellen (z.B. 
Karzinogene der Milchdrüse) gewonnen wurden. Das verwendete Mausmodell 
könnte also zu einem besseren Verständnis der Mechanismen dienen, welche die 
Aggressivität von Tumoren steuern.  
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IX. ADDENDUM 
1. Complete names of the genes found to be strongly and 
significantly regulated on RNA level 
Chip: Agilent Array           
Gen 
Symbol   Gen Name   Foldchange KO vs. WT  
    (week 1)   (week 3)   (week 6)   
          
 Mmp7   matrix metallopeptidase 7  1,1 2,7 4,8 
 Scube3  
 signal peptide, CUB domain, EGF-
like 3  1,3 3,7 4,4 
 Tff2  
 trefoil factor 2 (spasmolytic protein 
1)  1,4 2,4 4 
 Bex1   brain expressed gene 1  1 4,6 3,5 
 Fxyd6  
 FXYD domain-containing ion 
transport regulator 6  1 1,5 3,4 
 Bicc1   bicaudal C homolog 1 (Drosophila)  1,3 1,9 2,8 
 Aebp1   AE binding protein 1  0,9 1,6 2,8 
 Arhgap22  Rho GTPase activating protein 22  0,9 1,2 2,2 
 Adamtsl2   ADAMTS-like 2  1,2 1,9 2 
 Cdh1   cadherin 1 0,47 0,22 0,17 
 …   …  … … … 
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